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Epidermal Growth Factor Receptor is a tyrosine kinase receptor that is overexpressed in several 
tumors, and constitutes an ideal molecular target for new biologic therapeutic agents, as in lung and 
colo-rectal carcinomas [1]. The treatment with EGFR targeted therapies is always related to peculiar 
genetic abnormalities, as gene mutations and/or increased gene copy number. Clear cell renal cell 
carcinoma (CCRCC) has been widely investigated for EGFR protein expression, and previous studies 
on wide series of CCRCC demonstrated that EGFR protein expression is a common occurrence in 
CCRCCs, ranging from 50 to 90% of positive cases in different experiences [2]. So far, clinical trials 
data showed that EGFR-targeted molecular therapies are not effective for CCRCC. Since EGFR gene 
abnormalities are apparently not appreciable in CCRCCs, EGFR overexpression should be related to 
alterations in the post-translational regulation machinery, with anomalous protein stabilization or 
defective receptor downregulation, increasing its ligand-mediated activation. 
Nevertheless, since EGFR overexpression in CCRCC has been stated, further investigations on 
EGFR kinase and non-kinase roles is mandatory for widening the therapeutical adjuvant strategies 
for these tumors. 
Epidemiology of Renal Cell Carcinoma 
Renal cell carcinoma (RCC) is recognized as a heterogeneous group of tumors originating from 
the epithelium of renal tubules, which display distinctive genetic/molecular backgrounds, unique 
morphological features and characteristic clinical courses. The majority of kidney cancers (80-85%) 
are renal cell carcinomas (RCCs) arising from the renal parenchyma. The remaining 15- 20% are for 
the most part urothelial carcinomas of the renal pelvis [3].  
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RCC is the third most common lethal urological malignancy after prostate and bladder cancers 
[4]. It represents 3% of tumors in adults with an age-standardised rate incidence of 5.8 and mortality 
of 1.4 per 100,000, respectively, in more developed areas [5]. 
The incidence presents geographical variations, and it is generally highest in Europe, North 
America, and Australia. The lowest rates are reported in Japan, Asia, Africa and China. This 
variability suggests a strong role of exogenous factors in addition with geographic differences in 
genetic susceptibility and diagnostic variability [6,7]. 
Incidence worldwide per year is about 209,000 new cases and 102,000 patients die from this 
disease. In 2008, in Europe, 88,300 patients were diagnosed with RCC, and 39,230 died from the 
disease [8].  
According to Italian Cancer Registry, in Italy during the period 2003-2005, kidney cancer was 
the eighth most common malignancy in male population,  representing 3.8% in the overall incidence 
of tumors in men and 2.5% in women. The median incidence rate is 26.4 cases per 100,000 men and 
13.4 cases per 100,000 women per year, which corresponds about 9,800 cases per  year [9]. 
The incidence rate showed an increase among men and a substantial stability among women. 
This tumor has a North-South gradient with lower incidence in the Central and Southern regions. 
There is a 2:1 predominance of men over women, with the peak incidence occurs between the ages 
of 60 and 70 [9]. 
Approximately 20–30% of patients are diagnosed at the metastatic stage of disease and half of 
the remaining patients will experience recurrence after an initially curative treatment. The overall 5-
year survival rate of RCC is estimated in the range of 50%, whereas long-term survival decreases in 
case of metastatic disease and does not exceed 10% [5]. 
 Francesca Sanges - Analysis of EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma, 
Tesi di dottorato in scienze biomolecolari e biotecnologiche, Università degli Studi di Sassari 
3 
In the last few years, the incidence rate variation has been influenced by a greater use of 
diagnostic imaging, which has improved the diagnostic accuracy and increased the percentage of 
early diagnosis, thus expanding the therapeutic opportunities. 
Etiology and Risk Factors 
The information on risk factors for renal cell cancer was established by a large number of case-
control studies and recently supported by cohort studies [6]. Several risk factors for the development 
of RCC have been identified. No single risk factor explaining the development of all renal cell cancers 
has been found. Cigarette smoking, obesity, hypertension-antihypertensive medication and family 
history are the major risk factors identified for the development of renal carcinoma [7]. 
In heavy smokers, the risk is up to 2-fold compared to nonsmokers. Mutagens have been found 
in the urine of smokers, and the excretion correlate to the tar content [10,11].  
About obesity, the risk increases with an increased body mass index, both in men and women. 
It has been suggested that changes in levels of steroid-hormones, insulin like growth factor-1, 
cholesterol, vitamin D, adipose tissue derived cytokines and hormones, all obesity-related events, are 
involved in cancer development [12, 13, 14]. However, data on the prognostic impact of overweight 
in RCC is still conflicting. 
Hypertension increases the risk of Renal Cell Carcinoma, while the antihypertensive drugs such 
as diuretics are not independent risk factor [15]. 
The majority of renal cell cancers occur in sporadic form, whereas hereditary renal cancers 
account for a small proportion of the patients. A family history of disease is been associated with an 
increased risk of 4 times. The major hereditary forms include von Hippel Lindau syndrome, 
hereditary papillary renal cancer syndrome, RCC associated with hereditary leiomyomatosis 
syndrome, Birt-Hogg-Dubè syndrome and constitutional chromosome 3 syndrome. Recently, a rare 
form of familial renal cancer related to hyperparathyroidism-jaw tumor syndrome has been described. 
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Each of the inherited syndromes predisposes to distinct types of renal carcinoma, which tend to be 
multiple and bilateral, and present at an earlier age [16, 17]. 
The role of other risk factors, such as analgesics, exposure to asbestos, gasoline or 
trichloroethylene, as well as the potential protective effects of alcohol, fruit and vegetables, have to 
be taken into consideration in RCC oncogenesis. An association between renal cell cancer and 
disorders of the pre-existing kidney and urinary tract, including kidney stones and infections, has 
been proposed. These associations are statistically significant and have been confirmed in many 
studies [6, 18].  
Clinical Features 
Many renal masses are asymptomatic and non-palpable until the later stages of the disease. The 
classic triad of symptoms, consisting of flank pain, gross haematuria and a palpable abdominal mass, 
only occurs in 6-10% of cases [19]. 20% of RCC presents with systemic signs of advanced disease 
and among these, the most frequent are: declining weight up to cachexia, chronic low-grade fever, 
anemia, metastatic bone pain, chronic cough from pulmonary involvement. During the course of the 
tumor in 10-40% of cases, a paraneoplastic syndrome may be evident, which usually regresses after 
the removal of the tumor. Paraneoplastic syndromes result from the humoral release of various tumor-
associated proteins which are directly produced by the cancer cells or by the immune system in 
response to the tumor. Patients can suffer from symptoms due to metastases. The most frequent sites 
for RCC metastases are lung parenchyma, bone, liver and brain, but RCCs can metastasize to virtually 
any organ site [20]. 
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Classification of renal cell carcinomas  
The classification of renal neoplasia has undergone significant changes over the last 3 decades 
due to the large variety of histological subtypes and the continuous evolution of molecular methods. 
It is therefore difficult to create a simple and appropriate classification.  
The RCCs have historically been classified according to the cell type present (clear, granular, 
oncocytic or spindle) and according to the pattern of growth  (acinar, papillary, or solid); this 
classification criteria provided, however, limited information on clinical behavior of the cancer itself. 
A further histopathologic classification, proposed in 1986, was based on morphological, 
histochemical and ultrastructural tumor characteristics, and wass supported by cytogenetic and 
molecular analysis. 
Today these tumors are classified according to the system drawn up in 2004 by the World 
Health Organization (WHO), which describes categories and entities based on morphology, 
immunoreactivity and genetic features, in the light of new genetic alterations highlighted by the 
discoveries of recent years. Advances in understanding of basic morphology, immunohistochemistry, 
cytogenetics, and molecular pathology have led to an expansion in the number of distinct tumor 
entities which are currently recognized[21] . 
According to WHO 2004 classification, renal malignant tumors include those with the highest 
incidence, such as clear cell RCC, papillary RCC, chromophobe carcinoma, and collecting duct 
carcinoma of Bellini, and less frequent variants, as multilocular cystic RCC, carcinoma associated 
with Xp11 translocation / 2TFE3, carcinoma associated with neuroblastoma, mucinous tubular and 
spindle cell carcinoma. Oncocytoma, papillary adenoma, and metanephric adenoma are recognized 
as renal benign neoplasms [21]. 
Clear cell renal cell carcinoma (CCRCC) represents the wide majority of renal malignant 
neoplasms, accounting for approximately 70–80% of cancers [22].   
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Among less frequent neoplastic entities, papillary RCC represents 10-15% of kidney cancers 
and has a less aggressive clinical course than CCRCC. It has a tendency  to be multifocal and bilateral 
and consists of epithelial cells arranged to form papillae and tubules in variable proportions. 
Microscopically the papillae contains a delicate fibrovascular core with aggregates of foamy 
macrophages, cholesterol crystals and frequent hemosiderin granules. In 1997, two morphological 
types have been described: the type 1 contain a single layer of small cells with little cytoplasm 
covering the underlying fibrovascular cores, whereas the type 2 is constituted by pseudo-stratified 
cells with more eosinophilic cytoplasm and higher nuclear grade. The prognosis of  type 1 is more 
favorable than that of type 2. The commonest genetic alterations are trisomy or tetrasomy of 
chromosome 7, trisomy of chromosome 17 and loss of chromosome Y. Trisomy of 12, 16 and 20 is 
also found in PRCC and may be related to tumor progression, while loss of heterozygosity at 9p13 is 
associated with shorter survival [21, 22]. 
Chromophobe carcinoma accounts for 3–5% of RCCs and it is mostly sporadic, although some 
cases are related to the Birt-Hogg-Dubé (BHD) syndrome. Macroscopically it shows a demarcated 
beige or pale-tan color mass without  capsules. Microscopic examination reveals 2 types. The typical 
variant is characterised by huge pale cells with reticulated cytoplasm and prominent cell membrane. 
The eosinophilic variant is purely composed of intensively eosinophilic cells with prominent cell 
membranes. The cells have irregular, often wrinkled, nuclei. Some are binucleated. Nucleoli are 
usually small. Perinuclear halos are common. The underlying genetic abnormality is monosomy in 
chromosomes 1, 2, 6, 10, 13, 17 or 21[21, 22].  
Collecting duct or Bellini’s duct carcinoma represents less than 1% of RCCs.  It is characterized 
by irregular channels lined by a highly atypical epithelium, which can have a hobnail appearance. 
Renal medullary carcinoma is considered a subtype of collecting duct carcinoma and associated with 
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the sickle cell trait. Less than 3% of RCCs are characterized by indeterminate histological features 
and they are called unclassified or undifferentiated RCCs [21, 22].  
Some studies have shown that CCRCC has the worst prognosis compared to papillary and 
chromophobe variants. This concerns especially organ-localized tumors. When stage and nuclear 
grade were included in the analyses, tumor type lost independent prognostic significance. However, 
the multilocular cystic variant of CCRCC and mucinous tubular and spindle cell RCC have favorable 
prognosis. Collecting duct and medullary carcinoma have poor prognosis. For all the major subtypes 
sarcomatoid dedifferentiation is associated with adverse prognosis [21, 22]. 
Recently, the International Society of Urological Pathology (ISUP) Vancouver Classification 
of Renal Neoplasia proposed new epithelial neoplasms: tubulocystic renal cell carcinoma (RCC), 
acquired cystic disease-associated RCC, clear cell (tubulo) papillary RCC, the MiT family 
translocation RCCs (in particular t(6;11) RCC), and hereditary leiomyomatosis RCC syndrome-
associated RCC. In addition, 3 rare variants were considered as emerging or provisional new entities: 
thyroid-like follicular RCC; succinate dehydrogenase B deficiency-associated RCC; and ALK 
translocation RCC [23]. 
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CLEAR CELL RENAL CELL CARCINOMA 
CCRCC is the most common type of renal cancer that occur in adults who are older than 40 
years of age  and there is a 1,5:1 predominance of men over women [24]. It presents a mostly silent 
development and, for this reason, the diagnosis is made late in relation to the stage of the disease.  
The clinical onset is manifested by the classic triad of symptoms consisting of hematuria, back pain 
and an abdominal palpable mass. Other signs and symptoms of the disease frequently can be 
summarized as: anemia, liver dysfunction, weight loss, hypoalbuminemia, malaise general, 
hypercalcemia, and anorexia. Nevertheless, many patients are asymptomatic and the tumor, usually 
is diagnosed incidentally during abdominal imaging. 
Gross pathology 
Macroscopically, the tumor presents a bright yellow color due to the accumulation of lipids in 
malignant cells, and fibrosis, often at the center of the lesion, can impart a gray color [25]. The size 
of the tumor may vary from a few millimeters up to dimensions such as to reach a few kilograms in 
weight. Hyalinization and fibrosis are common in tumors in the early stage, while in advanced tumors 
coagulation necrosis can be observed [26]. The tumor is commonly well circumscribed, although the 
capsule is often absent [22]. A low percentage of cases presents cystic change and calcification or 
ossification. Bilateral tumors were found in 0.5-3% of patients, and are more frequent in patients with 
Von Hippel Lindau syndrome and tuberous sclerosis [25]. 
Microscopic features 
The microscopic analysis of CCRCC shows a proliferation of large cells, with well-defined cell 
membranes, and a clear, optically empty cytoplasm, caused by the removal of lipids by routine 
histological procedures. The tumor may also contain a variable proportion of cells with a residual 
granular eosinophilic cytoplasm, around the nucleus, but these are rarely the predominant cell type in 
the tumor. The nuclei appear round, oval and fairly regular in well-differentiated forms, where mitotic 
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activity is absent or rare, while they may show irregularities and hyperchromia with atypical mitotic 
figures in the most aggressive forms. CCRCC may progress into a sarcomatoid carcinoma, where a 
higher grade of cytological atypia is usually recognizable, even with multinucleated giant cells, and 
morphologic signs of dedifferentiation are apparent. 
Hyaline globules can be appreciable both outside and inside the cells [25]. From the 
ultrastructural point of view, the cells have long microvilli, reminiscent the brush border of the 
proximal renal tubules, while the Golgi apparatus and the rough endoplasmic reticulum tend to be 
scarce or absent, and may be pushed toward the cell periphery by the accumulation of lipids and 
glycogen [27]. 
The architecture of the tumor can be either alveolar, tubular and microcystic. In the alveolar 
pattern, the alveoli are rounded and separated by a light network of highly vascularized connective 
tissue whose blood vessels have a thin wall. In the tubular pattern, neoplastic epithelial cells are 
aligned to define a central lumen. In areas of microcystic degeneration, is generally present necrotic 
material and red blood cells, and cysts are separated by fibrous septa and irregular in shape and size. 
This type of architecture characterizes the rare variant known as multilocular cystic clear cell 
carcinoma [25]. The presence of poorly differentiated components of sarcomatoid or rhabdoid type 
is associated with a higher clinical aggressiveness [28]. 
Genomic Alteration 
CCRCC is characterized by a considerable molecular heterogeneity which results in an altered 
cell proliferation, cell death, metabolic activity and tumor microenvironment. This suggests that the 
traditional prognostic factors such as pathologic staging, grading according to Fuhrman and nuclear 
morphology may not be sufficient for a correct characterization and classification of these tumors. 
Therefore, it is difficult to predict the progression of the disease, the therapeutic response and 
survival. Over the past decade, the introduction of techniques as "new generation sequencing" has led 
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to significant progress in understanding the molecular pathogenesis of CCRCC by identifying specific 
genetic alterations and molecular mechanisms related to them. However, it remains a challenge still 
open the identification of prognostic and predictive biomarkers [29]. 
The most frequent genomic alteration detected in CCRCC is the loss of short arm of 
chromosome 3 at position 3p25 associated with von Hippel-Lindau (VHL) tumor suppressor gene 
inactivation that leads to a lack of functional VHL protein (pVHL). So it confirmed the critical role 
of VHL gene in CCRCC development. Over 800 VHL mutations were identified in both hereditary 
and sporadic CCRCC and  more than 50% of them are frameshift and nonsense mutations which 
produce loss of pVHL function[29, 30] . 
In familial forms, germ line mutations are followed by mutation, methylation, or loss of the 
remaining wild-type VHL allele in the tumor. Sporadic forms are characterized by somatic biallelic 
inactivation of the VHL gene. 80% of sporadic CCRCC displays alterations of the VHL gene which 
involve either somatic mutations, loss of heterozygosity and promoter hypermethylation but the 
effective biallelic inactivation of VHL is found in 60–70% of CCRCC cases [31-35]. Moreover, 30–
40% of sporadic CCRCCs have a functional VHL gene, suggesting that different genes and other  
pathways are involved in the tumor pathogenesis. 
The VHL gene is an evolutionarily well conserved tumor-suppressor gene composed of at least 
three exons. VHL gene coding for a protein of a 30-kDa (pVHL) constituted by 213 amino acids with 
multiple functions. 
The best investigated function is its role as a substrate recognition component of a multiprotein 
E3 ubiquitin protein ligase complex involving proteins such elongins B and C Cul2 and Rbx1, that 
target other protein for ubiquitination and subsequent proteasomal degradation [36]. The hypoxia-
inducible factor (HIF), the principal target, is a transcription factor that mediates adaptive responses 
to hypoxia. It enhances O2 delivery and promotes cell survival under a low oxygen environment by 
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upregulating numerous genes. HIF-1 is a heterodimer consisting of a hypoxia inducible alpha subunit 
and a constitutively expressed beta subunit [37-39]. 
HIF-1 is upregulated in the post-translational level through a decrease in protein degradation 
in response to hypoxia (O2-dependent mechanism). HIF-1 is also induced in the translational level, 
namely, by upregulation of its synthesis in response to growth factor stimulations and subsequent 
activations of phosphoinositol-3-kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR) or 
RAF/mitogen-activated protein kinase kinase (MEK)/mitogen-activated protein kinase (MAPK) 
pathways (O2-independent mechanism) [40]. 
Under normoxic conditions, pVHL binds the hydroxylated hypoxia inducible factor (HIF) alpha 
which leads to its ubiquitination and degradation [38]. 
Under hypoxic conditions or in the absence of functional VHL , the stabilization of HIF, which 
is not degraded, leads to the formation of a heterodimer with HIF1 which initiates enhanced 
transcription of HIF target genes VEGF, EGF, PDGF, erythropoietin, glucose transporter 1, involved 
Figure 1. VHL-HIF Pathway 
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in the regulation of cellular processes such as angiogenesis, cellular metabolism and cell growth 
(Figure 1).  
Both HIF1 and HIF2 show common but also distinct transcription patterns. HIF1 
preferably drives the expression of genes important for apoptotic and glycolytic pathways, whereas 
HIF2 activates genes involved in cell proliferation and angiogenesis. The inactivation of VHL 
resulting in overexpression of HIF may be involved in the development of cancer through 
deregulation of cellular processes described above [38]. 
The CCRCC can be classified according to the different mutational status and expression of the 
VHL and HIF genes, into three distinct CCRCC phenotypes tumors: the first with the gene wild-type 
VHL, and the absence of expression of HIF1α and HIF2α (VHL+, HIF1α-, HIF2α-); the second with 
mutated VHL with increased expression of both HIF1α that of HIF2α (VHL-, HIF1α+, HIF2α+); the 
third VHL deficient tumors with only overexpression of HIF2α (VHL-, HIF1α-, HIF2α+) [41]. 
Studies have shown that HIF-1 α inhibits transcription of the c-Myc oncoprotein, whereas HIF-2 α 
potentiates c-Myc transcriptional activity and cellular proliferation. Then both molecules oppositely 
regulate oncogene activation in CCRCC tumorigenesis, resulting in distinct gene expression patterns 
that correlate with differences in clinical outcomes. Another study has shown significant differences 
in gene expression profiles of VHL deficient CCRCC tumors. VHL +/+ cancers exhibit a specific 
gene expression pattern that may represent a separate CCRCC subset, which is not able to respond to 
VHL/HIF pathway targeted therapy [42]. 
Consequently, gene expression heterogeneity of CCRCCs clearly reflects differences in disease 
course, drug response variability among patients, tumor drug resistance, and therapy effectiveness. 
Furthermore, a recent study, using NotI-microarrays (NMA), a sensitive technology which 
allow to identify both genetic (deletions/amplification) and epigenetic (methylation/demethylation) 
changes simultaneously, identify epigenetic and genetic alterations of 22 genes located on 
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chromosome 3 in CCRCC. Among them there are well-known tumor suppressor gene and candidate 
(VHL, CTDSPL, LRRC3B, ALDH1L1 and EPHB1) and genes that were not previously considered 
involved in cancer development (LRRN1, GORASP1, FGD5, and PLCL2). These genes encodes 
proteins which are involved in signaling pathways and biological functions frequently affected during 
progression of different tumor, however a part of the gene and their protein functions are still 
unknown. These results suggest that methylation on chromosome 3 is a common event in CCRCC 
[43]. 
Recently a systematic large-scale sequencing of more than 3500 genes in 101 CCRCC 
identified new molecular markers correlated with clear cell renal cell carcinoma; these genes encode 
enzymes that demethylate (UTX, JARID1C) or methylate (SETD2) key lysine residues of histone 
H3. The epigenetic modifications of histone H3 regulate chromatin structure thereby influencing the 
control of gene transcription, in CCRCC such epigenetic mutations can be identified in only 15% of 
cases. PBMR1 gene mutations were found in 50% of tumors analyzed; the gene maps to chromosome 
3p21 and encodes the protein BAF180 representing the subunits of complex PBAF SWI / SNI that 
targets the chromatin remodeling it. This protein complex is involved in the regulation of replication, 
transcription, DNA repair, and control of cell proliferation and differentiation. Several studies identify 
the gene PBMR1 as a "gatekeeper" of CCRCC, suggesting a potential role for  therapeutic options 
[39] . The high incidence of mutations in the PBRM1 gene (50% of cases) were confirmed in 
independent CCRCC sets, which makes the PBRM1 gene a second major mutated gene in CCRCC 
(following VHL) [44, 45]. Moreover, loss of PBRM1 protein expression correlates with clinical 
parameters, including advanced tumor stage, low differentiation grade and, worse patient outcome 
[46]. Mutations in the BAP1 gene, a protein associated with BRCA, were identified in 15% of clear 
cell renal carcinomas, indicating that mutations in the BAP1 gene and the gene PBRM1 are mutually 
exclusive. Other studies have demonstrated the presence of amplification of chromosome 8q resulting 
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in overexpression of c-MYC gene. Finally, the RASSF1A gene is hypermethylated and inactivated 
in 30-50% of sporadic cases of clear cell renal cell carcinoma and papillary, while rarely found gene 
mutations.  
The second most frequent chromosomal alteration is the duplication of chromosome 5q but the 
oncogenes located in this region remain unknown. Several studies indicate that the candidate genes 
mapped to 5q chromosome are TGFB1 amplified in 70% of CCRCC cases and CSF1R upregulated 
in 30% of tumors [47, 48]. 
Other common polysomy are those of chromosomes 7 (18-30%), 16 (11%), 12 (10-15%), 20 
(10%), and 2 (9-14%). During the progression of the disease, the cancer cells can also express the 
entire polyploidy karyotype, in turn, associated with more losses and gains of chromosomal material 
transcription, DNA repair, control of cell proliferation and differentiation [49]. 
Prognostic Categorization 
In assessing the prognosis of CCRCC, we take into account several clinical-pathological 
features, such as pathological staging according to the TNM system (tumor, node, metastasis), where 
T stands for tumor size, N for lymph node status and M for the presence of metastases; Fuhrman 
nuclear grade, which correlates with tumor aggressiveness; the presence of necrosis.  
To date, different prognostic models to predict survival and identify patients with a high risk of 
recurrence, have been proposed. The SSIGN Score, a model that integrates stage, size of primary 
tumor, nuclear grade and presence of necrosis in a single score, has proven particularly useful for 
predicting the '"outcome" of the patient. In fact, higher SSIGN score are correlated with reduced 
tumor-specific survival in patients with clear cell renal cell carcinoma.  
In a multivariate retrospective analysis of 600 patients with metastatic renal cell carcinoma 
Elson et Coll have identified five indicators of survival: ECOG PS score ( Eastern Cooperative 
Oncology Group Performance Status), the period of time between diagnosis and the first systemic 
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treatment, the number of metastatic sites, previous systemic therapy and weight loss. On the basis of 
these factors, the authors have stratified patients in five group characterized by different survival.  
The UCLA Integrated Staging System (UISS system), developed by Zisman et al, is valid for 
patients with metastatic RCC and with localized tumors [50].  
It is a model that integrates the TNM staging, ECOG PS, and Fuhrman grade and categorize 
patients into three groups (low, intermediate, and high risk) to predict overall survival. In an 
international multicenter this system has not been confirmed to be reliable and accurate for metastatic 
disease therefore retains its prognostic value only in localized disease [51].  
The Memorial Sloan Kettering Cancer Center (MSKCC) prognostic system was proposed by 
Motzer et al, who analyzed a series of 670 patients with RCC in advanced stage and treated with 
immunotherapy and chemotherapy, identifying five pretreatment factors significantly correlated with 
a worse prognosis: low Karnofsky Performance Status (KPS) , high lactate dehydrogenase (LDH) 
and serum calcium , low hemoglobin and presence/absence of nephrectomy [52]. 
Motzer, using these variables, stratified patients into the following groups: favorable, 
intermediate, and unfavorable risk with different prognosis, survival ranged from 20 months for the 
group with a good prognosis, 4 months for a poor prognosis. A subsequent validation of the Motzer 
prognostic system has shown that the majority of patients fall within the intermediate-risk group and 
no account is taken of independent prognostic factors such as the previous radiation treatments and 
the number of metastatic sites. The addition of these two parameters allowed to redistribute patients 
initially considered to be at intermediate prognosis and classify  them in the group with a poor 
prognosis. 
Motzer et al. also have developed a nomogram which should be able to predict the probability 
of disease progression at 12 months after start of treatment, using parameters that are an evolution of 
Motzer prognostic criteria [53].  
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New prognostic markers 
The wide application of immunohistochemical and molecular techniques has allowed to 
identify new potential prognostic markers and their potential prognostic impact. They are represented 
by adhesion molecules, as E-Cadherin-6; molecules induced by hypoxia, as VEGF, HIF, CAIX; 
molecules stimulating immunosuppressive responses, as B7-H1 and B7-H4; and anti-apoptotic 
molecules, as surviving [54, 55].  
VEGF is a polypeptide overexpressed in the tumor, which has been associated with a decreased 
survival time and it is correlated with tumor size, grading, necrosis, stage and microvessel invasion. 
Increased production of VEGF is relate to VHL gene alterations [56, 57]. HIF is a typical tumor 
marker, and its correlation with the survival of patients with CCRCC has been extensively studied; 
in fact, HIF1α is overexpressed in all renal neoplasms, but the clear cell subtype is the one with the 
largest share of expression; HIF2α is also overexpressed in the epithelium of numerous tubular renal 
tumors, instead both HIF1α that HIF2α, in at least 50% of the cases, are not expressed in sarcomatoid 
component of the tumor [58, 59]. Multivariate analysis demonstrated that patients with HIF1α 
expression and sarcomatoid differentiation  showed higher PFS and cancer-specific survival (CSS) 
rate.  On the contrary HIF2 α expression was not associated with survival [55]. 
Carbonic anhydrase IX (CAIX) is currently one of the factors most studied and is a 
transmembrane protein, involved in the regulation of both intracellular and extracellular pH, whose 
gene expression is modulated by HIF1. Although CAIX is absent in the context of normal renal 
parenchyma, is overexpressed in 95% of clear cell carcinomas and in 50% of papillary [60]. Some 
authors have demonstrated the role of CAIX in predicting cause-specific survival of patients with 
clear cell carcinoma.  
B7-H1 and B7-H4 are members of the super-family of immunoglobulins, in particular B7-H1 
is a glycoprotein expressed on the cell membrane, which acts as activator of T lymphocytes, and is 
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correlated to a high degree of mortality in renal tumors, while B7-H4 is expressed in activated T cells 
[61, 62].  
Survivin is an inhibitor of apoptosis protein detectable in all renal tumors, whose 
overexpression has been associated with adverse tumor features and poor prognosis [63, 64].  
Some chromosomal alterations in RCC have been related with prognosis: in fact, the deletion 
of the short arm of chromosome 3 was associated with more favorable prognosis, while the loss of 
4p, 9p, and 14q is associated with poor prognosis.  
Treatment 
The treatment of renal cell carcinoma has changed dramatically in recent years with the advent 
of targeted agents. 
The therapeutic approach is primarily surgical, in particular in patients with early-stage disease, 
although about 30% of patients will display tumor recurrence and distant metastases. Depending on 
the size and extent of the tumor, a partial or total nephrectomy may be performed, and recently new 
laparoscopic procedures have been developed in order to improve the recovery of the patient.  
Chemotherapy, which appears to be active in many solid tumors, resulted in a minimal clinical 
benefit in patients with renal cell carcinoma because no chemotherapeutic agent shows significant 
antitumor activity. Currently the indications for chemotherapy in metastatic renal cell carcinoma are 
limited to specific clinical conditions. 
Since RCC is highly resistant to chemotherapy, the treatment is based on the administration of 
immunomodulatory agents such as interleukin-2 (IL-2) and / or interferon-alpha (IFN-α) with a 
significant antitumor activity, widely used as first-line treatment of metastatic disease. Response rates 
with these cytokines are low (5 to 20%), and median overall survival is approximately 12 months. 
Interleukin-2 (IL-2) is a cytokine produced by activated T cells. Upon binding with specific 
receptor on the cell membrane, IL-2 promotes clonal expansion and enhances the cytotoxic activity, 
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which is in an increase in the proliferation and cytolytic functions of cellular effectors, such as CD8+ 
cytotoxic T lymphocytes and "natural killer" cells. 
The interferons are natural glycoproteins with antiviral, antiproliferative, and 
immunomodulatory properties. Interferon-alpha (IFN-α) is a protein produced by lymphocytes, 
lymphoblasts and macrophages which is able to activate macrophages and monocytes, to increase the 
activity of the 'natural killer' cells, to induce the expression of antigens on the cell surface, and to 
enhance the activity of cytotoxic T lymphocytes. IFN-α antineoplastic mechanisms are not clear, but 
an important activity as anti-angiogenic modulator, especially when it is administered at low doses, 
has been reported.  
The percentage of patients showing a complete response, especially with IL-2, was very limited, 
i.e. approximately 12.4% of patients, and it was often associated with significant toxicity. In addition, 
it was shown that the benefit of immunotherapy was limited to patients with good prognosis: recent 
data show a higher response rate in patients treated with high-dose IL-2 and selected on the basis of 
specific clinics characteristics [65]. 
Since 2005, new molecules for the treatment of metastatic renal carcinoma have been 
developed, based on new findings concerning the biological mechanisms responsible for the renal 
carcinogenesis. 
The development of "Targeted Therapies" has enabled to develop more personalized treatment 
but also improved the clinical outcome of patients with metastatic renal cell carcinoma. The median 
survival of patients with metastatic renal cell carcinoma treated with cytokines was about 10 months, 
whereas an improvement in progression-free survival of disease up to 27 months, and an increase in 
overall survival up to 40 months, has been estimated for targeted treatments. 
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TARGETED THERAPIES 
Recent advances in molecular biology have allowed to study the different expression of genes 
involved in neoplasms and proteins produced by them in order to determine a detailed molecular 
profile of tumors. 
The resulting clinical and therapeutic application of these studies made it possible to customize 
therapies based on tumor biomolecular characterization.  
The Targeted Therapy is defined as a drug that blocks the growth and spread of cancer by 
interfering with specific molecules involved in tumor growth and progression. 
The major advantage of targeted therapies is the selective action on tumor cells, making them 
potentially more effective and less toxic, as well as the enhancement of therapeutic effects of 
chemotherapy and radiotherapy. Moreover, data obtained from clinical research support the 
possibility of using a wide range of agents directed to different molecular targets. The greater 
restriction on their use is now represented by spectrum of activity limited to those particular 
subgroups of tumors sharing the same histologic phenotype, depend on specific molecular alterations. 
Main mechanisms of action of identified for targeted therapies are: blocking of growth factors and 
their receptors, modification of the function of proteins involved in the regulation of gene expression 
or other cellular functions, induction of apoptosis, inhibition of tumor cell 'angiogenesis, 
enhancement of the immune response against cancer cells and production of toxic molecules against 
cancer cells (Figure 2). 
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Figure 2. Targeted therapies mechanism of action  
Recently, protein kinases, especially protein tyrosine kinase, which catalyse key 
phosphorylation reactions in signaling cascades affecting every aspect of cell growth, differentiation 
and metabolism, have become the main therapeutic target in cancer treatment [66]. 
Most extracellular signals, implicated in the regulation of growth and cell survival, are 
amplified and transduced into the cell through three processes: the activation of receptor tyrosine 
kinase , receptors coupled to GTP-binding proteins, or through the cytokine receptors [67]. All these 
receptors systems, directly or indirectly, involve protein kinases in signal transduction. The 
development of cancer can be correlated with a wide variety of cellular mechanisms that include the 
overexpression of growth factors, such as the vascular-endotelial growth factor (VEGF), the 
transforming growth factor alpha (TGF-alpha), receptors of growth factors (the receptor for platelet-
derived growth factor, PDGFR, or receptor for the epidermal growth factor, EGFR), the deregulation 
of kinase (ABL or EGFR), the deregulation of the activity of kinases by the activation of oncogenes 
(via signal transduction Ras/Raf), the loss of function of tumor suppressor genes (p53, pRb). 
The knowledge of signal transduction pathways and the method by which a cell responds to 
external signals have made that the protein-kinase, could become an important target for the treatment 
of cancer, especially in cases where an inappropriate activation of these kinase protein is involved in 
the pathogenesis and progression of cancer [66.]. 
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Study and comprehension of molecular mechanisms involved in the pathogenesis of tumors, 
have allowed the identification of markers useful both for diagnosis and as targets for therapeutic 
treatment. The resulting clinical and therapeutic application of these results is allowing to customize 
treatments based on biomolecular characterization of the tumor. More and more are using selective 
drugs that act on single altered molecules (growth factors, receptors, enzymes, etc.), responsible for 
the growth and uncontrolled spread of cancer cells, their resistance to traditional therapies and 
angiogenesis.  
Among the targets proposed by the new selective therapies, used in the treatment of cancer, 
there are a number of molecules with antigenic properties, generally localized to the cell membranes 
and expressed in a different way from the neoplastic elements than normal cells, potentially 
susceptible to the action of targeted humanized monoclonal antibodies. This therapeutic approach 
was reflected particularly in the adjuvant treatment of breast cancer, colon cancer, lung cancer and 
certain lymphoproliferative disorders [68, 69]. 
Clear examples of their potential efficacy are given by Imatinib-mesylate, which was approved 
for chronic myeloid leukemia and Gastro Intestinal Stromal tumors (GIST), mesenchymal neoplasms 
that develop in different sections of the gastrointestinal tract, characterized by the presence in the 
tumor cells of c-KIT and PDGFR-alpha gene mutations resulting in gain of function of the 
corresponding receptor. It is known that GISTs are poorly responsive to conventional treatments such 
as chemotherapy and radiotherapy, and excellent results were recently obtained with Imatinib-
mesylate treatment. Reports in the literature indicate that 75-90% of patients with advanced-stage 
GISTs treated with Imatinib-mesylate show clinical benefits. 
Trastuzumab, a humanized monoclonal antibody specific for the human epidermal growth 
factor receptor type 2 (HER2), a cell-surface tyrosine kinase receptor overexpressed by 25% to 30% 
of breast cancers, was approved as a single agent in first-line treatment of HER2-Overexpressing 
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metastatic breast cancer. Patients with HER2 positive Breast Cancer manifested short disease-free 
and overall survival. A large phase II trial prove that trastuzumab monotherapy is active against 
HER2-overexpressing breast cancer in patients previously treated with chemotherapy for metastatic 
disease. Additionally, the results of a phase III trial 7 indicate that trastuzumab significantly enhances 
the activity of first-line chemotherapy and provides a survival advantage to women with HER2-
overexpressing breast cancer. 
In 2007, Bevacizumab, a recombinant humanized monoclonal antibody that binds to vascular 
endothelial factor (VEGF) inducing angiogenesis inhibition, was approved for the treatment of 
patients with metastatic HER-2 negative breast cancer. The approval was based on a Phase 3 study 
that showed that Avastin in combination with paclitaxel is able to reduce by 52% the risk of tumor 
progression or death compared to patients treated only with chemotherapy, doubling-free disease 
survival. [70] 
Another example is Cetuximab, an EGFR inhibitor, utilized for the treatment of non-small cell 
lung cancer (NSCLS). About 70% of cases of lung cancer shows overexpression of EGFR which 
correlates with a poor prognosis, EGFR genomic amplification and activating mutations of the 
receptor. 
RCC and Targeted Therapies 
Small molecule tyrosine kinase inhibitors (TKIs) were the first targeted therapies approved for 
the treatment of RCC. They bind to tyrosine kinase receptors located on the intracellular domain of 
cell surface growth factor receptors, blocking intracellular signaling, and therefore promoting tumor 
shrinkage. 
For the treatment of CCRCC different types of drugs have been developed: the first class 
includes drugs aimed to inhibit neoplastic angiogenesis, such as Bevacizumab, a monoclonal antibody 
directed against the vascular endothelial growth factor (VEGF); a second class includes tyrosine 
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kinase inhibitors (TKIs) such as Sunitinib, Sorafenib, Pazopanib, and Axitinib, in addition to mTOR 
inhibitors, Everolimus and Temsirolimus (Figure 3). Each of these molecules acts specifically against 
a component of the intracellular molecular mechanisms that characterize the renal carcinoma. These 
agents mostly focus on downstream disruption of the VHL/HIF pathway by targeting VEGFR, or 
inhibiting the mTOR pathway. 
VEGF is a potent pro-angiogenic protein, leading to increased vascular permeability and 
endothelial cell proliferation/migration. Therapeutic inhibition of the VEGF pathway thus has strong 
biologic rationale in RCC. 
Sorafenib, approved in 2005, is a multikinase inhibitor which was designed as a c-Raf and b-
Raf inhibitor. The Ras/Raf signaling pathway is a mediator of tumor cell proliferation and 
angiogenesis. 
Sorafenib is a TKI that inhibits VEGFR2 and 3, c-Kit, PDGFR and the serine-threonine kinase 
BRAF and CRAF (kinase components of the molecular cascade of RAF / MEK / ERK pathway, 
which is involved in survival / proliferation of cells cancer). Sorafenib is used as a second-line RRC 
treatment due to improved progression-free survival (PFS) when compared with cytokine therapy. In 
a clinical phase III trial patients with metastatic RCC, progressing after prior treatment with 
cytokines, were randomized to receive II line treatment with Sorafenib versus placebo. [71] 
The benefit in terms of PFS after therapy with Sorafenib was statistically significant. In a 
subsequent randomized study phase II comparing Sorafenib vs. IFN-α as treatment of the line, in 189 
patients with metastatic RCC, no statistically significant difference between the two drugs were 
reported. In elderly patients (> 70 years), Sorafenib was effective and safe in the same way as shown 
for younger patients with a toxicity profile slightly higher in elderly patients, although the difference 
was not statistically significant. 
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Sorafenib has been approved in II line therapy for patients with RCC metastatic progression 
after cytokine therapy or to the line of patients candidates for treatment with cytokines [72]. Oral 
Sorafenib therapy prolonged PFS in patients with advanced CCRCC in whom first-line therapy had 
failed. This improvement was associated with an increased number of adverse events, as compared 
with placebo. 
Sunitinib is an oral inhibitor of  VEGFR1 and 2, PDGFR alpha and beta, FGFR1, FLT-3, CSF-
1R and c-KIT, was approved by the Food and Drug Administration (FDA) for the treatment of RCC, 
and is recommended as first-line treatment in advanced stages [73]. A randomized phase III trial, 
Sunitinib to IFN-α in first-line therapy in 750 patients with metastatic RCC, showed a statistically 
significant advantage for PFS. Sunitinib is very effective in patients with metastatic CCR. Moreover, 
it has also shown activity in patients with unfavorable characteristics of the disease (2 brain 
metastases, non-clear cell histology) and in elderly patients [74] 
Sunitinib is an oral inhibitor of  VEGFR1 and 2, PDGFR alpha and beta, FGFR1, FLT-3, 
CSF-1R and c-KIT, which has been approved in 2006 by the Food and Drug Administration (FDA) 
for the treatment of CCRCC, and is recommended as first-line drug in treatment of the advanced 
stages. Two multicentre phase II trials  investigated Sunitinib’s efficacy as second-line therapy for 
patients with a prior nephrectomy and cytokine-refractory RCC [75, 76].  
Both trials demonstrated that Sunitinib is active in the second-line setting with overall response 
rate RRs of 40 and 33% and PFS of 8.7 and 8.8 months .A randomized phase III trial confirmed the 
results of the phase II studies and compared Sunitinib with IFN-a in 750 patients with untreated 
metastatic clear cell RCC, showing a statistically significant advantage for PFS. Moreover, it has also 
shown activity in patients with unfavorable characteristics of the disease (2 brain metastases, non-
clear cell histology) and in elderly patients [77].  
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Pazopanib, targeting VEGFR 1– 3, PDGFR α and β, FGFR1, FGFR3,KIT, and CSF-1R, has 
more recently been approved for use as a first-line therapy for metastatic RCC. A phase III trial reports 
that Pazopanib may have a favorable side effect profile as compared to Sunitinib, although 
hepatoxicity is more frequent with Pazopanib. A randomized, double-blind, phase III study evaluated 
efficacy and safety of Pazopanib monotherapy demonstrating significant improvement in PFS and 
tumor response compared with placebo in treatment-naive and cytokine-pretreated patients with 
advanced and/or metastatic RCC [78]. 
Pazopanib is likely to be indicated in the treatment of patients with locally advanced or 
metastatic CCR, with predominant clear cell histology:, in patients with good prognosis / intermediate 
(according to MSKCC Prognostic Score); in line II, in patients previously treated with cytokines. 
Axitinib, a second-generation inhibitor of VEGFR 1, 2, and 3 at sub-nanomolar drug 
concentrations. It is a small molecule approved by the FDA as a second-line therapy of advanced 
renal cell carcinoma. Axitinib resulted in significantly longer PFS compared to another multikinase 
inhibitor, Sorafenib, and was developed to be a more potent and selective inhibitor of VEGFRs [79]. 
Relative potency of Axitinib is 50–450 times greater than that of the first-generation VEGFR 
inhibitors. Additionally, first-generation inhibitors block other targets, such as  PDGFR,  b-RAF, KIT, 
and FLT-3, which are not inhibited by Axitinib. These off-target activities might  contribute to the 
adverse effects of the first-generation inhibitors, suggesting that more specific inhibitors of VEGFR 
such as Axitinib might have an enhanced therapeutic efficacy. In a phase 2 study including 13 patients 
with cytokine-refractory renal cell carcinoma, the objective response rate with Axitinib was 44%, 
with a median time to progression of 15-7 months and an overall survival of 29-9 months.  
Bevacizumab, a monoclonal antibody, given intravenously, that binds to and neutralizes 
circulating VEGF protein but does not affect the VEGF receptor, approved by FDA for colon cancer 
in 2004 and for other cancers, including RCC in 2009. This antiangiogenic antibody has produced a 
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signiﬁcant prolongation of time to disease progression compared with placebo in patients with 
treatment-refractory metastatic RCC in a small randomized trial [80].  
Bevacizumab it is not approved for RCC monotherapy but in combination with the immune 
modulator interferon alpha, producing high response rate and PFS exceeding 10 months. 
Indeed, a prospective randomized trial demonstrates that addition of Bevacizumab to IFN 
produces significantly prolonged PFS and a higher ORR compared with IFN monotherapy in patients 
with untreated metastatic clear-cell RCC [81]. This is the first demonstrations of the benefit of 
combining multiple non chemotherapy agents in cancer systemic therapy. It is noteworthy that the 
mechanism of these two agents may not be entirely independent, as IFN has demonstrated 
antiangiogenic effects and antibody-mediated VEGF inhibition has antitumor effects through 
improvement in dendritic cell function.  
Two agents targeting the mTOR pathway are FDA approved for the treatment of RCC: 
temsirolimus and everolimus. 
Temsirolimus is a derivative of Sirolimus (rapamycin), it is an inhibitor of mammalian target 
of rapamycin kinase, mTORC1, administered intravenously and approved for first line treatment of 
RCC. mTOR is a component of RAS/PI3K/PKB intracellular signaling pathways regulating cell 
growth and proliferation, metabolism, and angiogenesis, which is involved in the cell growth and 
proliferation, and in the response of such cells to hypoxic stress. Abnormal functioning of the mTOR 
pathway may contribute to the pathogenesis of renal cell carcinoma (RCC) [65]. Interruption of 
mTOR signaling decreases levels of HIF, VEGF, and other intracellular factors involved in 
progression of the cell through its cycle.  It is the only drug recommended as a category 1 therapy for 
RCC patients with poor prognosis.  
Everolimus is an immunosuppressant mTOR inhibitor, orally administered, approved by the 
FDA in 2009 in patients with advanced RCC after progression following treatment with Sunitinib or 
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Sorafenib. According to a trial involving 410 RCC patients previously treated with inhibitors of 
VEGF and subsequently with Everolimus, a prolonged PFS compared to placebo was appreciable 
[82].  
It is known that EGFR overexpression is correlated with a poor prognosis in CCRCC, reduced 
survival and increase risk of metastatic disease. Clinical trials have shown that EGFR inhibitors, when 
used as single agents, did not demonstrate treatment efficacy in patients with advanced RCC. 
Phase II trials, open label study showed that patients with advanced, metastatic, or relapsed 
RCC did not reveal any objective responses following treatment with Gefitinib (IRESSA), the first 
EGFR tyrosine kinase inhibitor to be approved for the treatment of cancer [83].  
In another study by Drucker et al. involving 18 patients with advanced RCC treated with 
IRESSA compared with IFN-the treatment did not result in any complete or partial responses, and 
13 patients (81%) had progression of disease within 4 months after onset of therapy [84].  
Figure 3. Targeted therapies for renal cell carcinoma and biological pathways 
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This lack of objective responses in patients with metastatic RCC has also been observed in a 
phase II trial of the EGFR monoclonal antibody Cetuximab (ABX-EGF), where time to progression 
was not prolonged with Cetuximab compared with IFN- data [85] 
Neoadjuvant biological therapy is the administration of "targeted" before nephrectomy, with 
two different objectives: reduce the volume of the primary tumor in patients with CCR to allow partial 
nephrectomy; reduce the volume of the primary tumor and the extent of metastatic spread in patients 
with metastatic CCR. 
To date, neoadjuvant therapy is a treatment modality currently under study, which is not to be 
considered, at the moment, in routine clinical practice. 
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EPIDERMAL GROWTH FACTOR RECEPTOR 
Epidermal growth factor receptors represent a large family of tyrosine kinase receptors (TKR) 
expressed in several types of cancer, including breast, lung, esophageal, and head and neck [86] 
EGFR and its family members are the major contributors of a complex signaling cascade that 
modulates growth, differentiation, adhesion, migration and survival of cancer cells. Given their 
multidimensional role in the progression of cancer, they have emerged as attractive candidates for 
anti-cancer therapy. 
Specifically EGFR is one of the most investigated TKRs, is constitutively expressed in some 
normal mammalian epithelial cells where has been shown to regulate a variety of important functions, 
including growth, survival, differentiation, and morphogenesis. It may be used as a model for 
understanding signal transduction pathways.   
The epidermal growth factor receptor (EGFR) is a member of the human epidermal growth 
factor receptor (HER)-erbB family of receptor tyrosine kinases, which also includes HER2/neu 
(erbB2), HER3 (erbB3), and HER4 (erbB4) (Figure 4). These receptors are widely expressed in all 
tissues and they activate a wide range of biological responses including mitogenesis, migration, 
differentiation, apoptosis and dedifferentiation. [87] 
EGFR is a transmembrane protein of 170 kD which comprises a polypeptide chain of 1186 
amino acids encoded by a gene that maps to the short arm of chromosome 7.  
EGFR consists of an extracellular N-terminal ligand binding domain and a dimerization arm, a 
lipophilic region transmembrane domain, and an intracellular, highly conserved, cytoplasmic c-
terminal tyrosine kinase domain that is able to phosphorylate tyrosine residues on different 
intracellular adaptor proteins (Figure 5).  
The extracellular domain of the receptor is variable and it enables binding to different ligands. 
It is divided into 4 sub-domains (I-IV): the sub-domains I and III mediate ligand binding, while the 
 Francesca Sanges - Analysis of EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma, 
Tesi di dottorato in scienze biomolecolari e biotecnologiche, Università degli Studi di Sassari 
30 
sub-domains II and IV are rich in cysteine residues, are involved in receptor dimerization. The 
extracellular domain in the absence of ligand is shown as a closed domain. This inactive conformation 
presents intramolecular interactions between the regions II and IV, preventing the formation of a 
binding pocket for the ligand. In the presence of ligand, the sub-domains II and IV are opened 
allowing the sub-domains I and III to form a binding pocket for the ligand, which results in 
dimerization of the receptor (Figure 6).  
The intracellular domain comprises three domains: a juxtamembrane region (JM), a tyrosine 
kinase domain (kinase) and a carboxy-terminal regulatory region (CT). The JM region has been 
reported to have a number of regulatory functions including regulation of downstream proteins and 
ligand-dependent receptor internalisation [88, 89] (Figure 5). 
Many different ligands are able to bind to the EGFR extracellular domain such as, epidermal 
growth factor (EGF), transforming growth factor–alpha(TGF-α), amphiregulin (AR), betacellulin 
(BTC), heparin-binding EGF-like growth factor (HB-EGF), epiregulin (EPR), epigen (EPG) and 
neuregulins 1-6 (NRG). EGF, TGF-α, AR, BTC and EPR bind specifically EGFR and among these 
EGF, TGF-α are the most important ligands.  
 
Figure 4. EGFRs family and specific ligands 
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Figure 5. Structure of the EGF receptor 
 
 
Figure 6. Model for molecular mechanism of ligand-induced EGFR activation. 
The stimulating factors (ligands) bind to the extracellular domain causing receptor homo- or 
hetero-dimerization, thus inducing conformational change of the intracellular phosphorylation 
components, enabling downstream signaling. The downstream signaling cascades include the RAS-
RAF-MAP-Kinase pathway, the phosphatidylinositol 3–Kinase and the Akt pathway. These signaling 
pathway participate in cell cycle activation, cell survival, proliferation and angiogenesis. EGFR 
pathway stimulation has been shown to promote tumor cell motility, adhesion, and metastasis [90]  
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Signal transduction pathways activated by EGFR 
The binding of epidermal growth factor or other growth factors to the EGFR determines its 
dimerization, which is followed by the activation of intracellular protein kinases through 
phosphorylation, giving, thus, the origin signal transduction. The signal transduction pathways 
activated by EGFR control different cell functions such as growth, apoptosis, differentiation, and cell 
migration (Figure 7) [91].  
PI3K/Akt/mTOR signalling pathway 
Studies demonstrated that the PI3K/Akt/mTOR pathway plays a crucial role in many biological 
processes including proliferation, differentiation, anti-apoptosis, tumorigenesis and angiogenesis 
[92]. Furthermore, this pathway has been shown to be involved in the regulation of a variety of 
cancers including breast cancer [93], lung cancer [94], melanomas [95] and leukaemia [96]  
The phosphatidyl-inositol-3-kinase (PI3K) are a family of heterodimeric proteins consisting of 
a catalytic subunit and a regulatory that phosphorylate PIP2 (phosphatidylinositol) in PIP3 
(fosfatidyltriinositolo). The PI3K are divided into three classes (I, II and III) according to protein 
domains that constitute them and the specificity of the substrate.  
Class I PI3K are cytoplasmic heterodimers composed of a catalytic subunit (p110) and an 
adaptor protein (p85), which contains two SH2 and one SH3 binding domain. The Class I PI3K can 
be further divided into the Class IA isoforms, which is activated by RTKs, and the Class IB, which is 
activated by Gβγ subunits of GPCRs. The Class I PI3K are the only ones that are able to convert 
phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) to the second messenger phosphatidylinositol-
3,4,5-triphosphate (PI-3,4,5-P3) [92]. Class II PI3Ks, which comprise three catalytic isoforms 
including C2α, C2β and C2γ, are mainly associated with the phospholipid membranes. This class of 
PI3K produces PI-3,4,5-P3 from phosphatidylinositol and may also produce PI-3,4-P2 from 
phosphatidylinositol-4-phosphate (PI-4-P) [97]. The structure of Class III PI3Ks are similar as Class 
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I, as they are heterodimers composed of a catalytic subunit (Vps34) and a regulatory subunit (p150). 
They produce PI-3,4,5-P3 through the conversion of phosphatidylinositol [98]. 
Akt is the most important downstream effector of PIP3 and is involved in the regulation of 
different physiological processes such as the proliferation, differentiation, apoptosis, transcription, 
translation and metabolism.  
Akt is a serine/threonine protein kinase which belongs to the cyclic adenosine monophosphate 
(cAMP)-dependent protein kinase A/protein kinase G/PKC super family. In mammals, three 
members of Akt have been identified, Akt1 [99], Akt2 [100] and Akt3 [101]. Isoforms consist of 
three domains: an amino terminal pleckstrin homology domain, a central kinase domain and a 
carboxyl-terminal regulatory domain. 
Akt is activated through a double phosphorylation and subsequent recruitment of the protein to 
the cell membrane. Through its PH domain, present at the N-terminus of the molecule, is in fact able 
to bind molecules of PIP3 present at the level of the plasma membrane. The recruitment of Akt to the 
cell membrane causes a conformational change that allows the molecule to its residual thr308 to come 
phosphorylated by PDK1, a serine / threonine kinase containing a PH domain, while the second 
phosphorylation, occurs on the serine residue in position 473 to place level of the C-terminal end of 
the protein complex and is determined by the mTOR (mammalian target of rapamycin) / Rictor 
(rapamycin-insensitive companion of mTOR) . 
Akt is phosphorylated migrates in both the cytoplasm and nucleus, with a prevalence in this 
second cell compartment since most of its targets have a cytosolic localization.  
Given the importance of Akt in control of both proliferation and cell survival, alterations in the 
PI3K-AKT signaling pathway are a key point in the onset and progression of many cancers. There 
are many, in fact, human tumors with mutations and chromosomal rearrangements at the level of this 
pathway.  
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mTOR is a serine/threonine kinase that regulates various biological effects including cell 
proliferation, survival, motility, protein synthesis and transcription [102]. The major function of 
mTOR is the regulation of translation, especially the recruitment of ribosomes to mRNA. mTOR 
directly or indirectly regulates the activation of several components of the ribosomes recruitment 
mechanism 
Ras/Raf/MAPK pathway  
The Mitogen-Activated Protein (MAP) kinases are a group of serine / threonine kinases that 
mediate many regulatory signals. There are three main groups of MAP kinase: the family of p38 MAP 
kinase, the family of extracellular signal-regulated kinase (ERK) and the family of kinase N-terminal 
c-Jun (JNK). The different members of the signal transduction pathway controlling important cellular 
functions such as cell survival, apoptosis and transcription; their abnormal activation is responsible 
for malignant transformation and tumor progression. In recent years, numerous studies have 
established that the route of the Ras/Raf/MAPK is closely linked to via PI3K-Akt; in fact, the 
activated Ras protein is able to regulate both pathways. [103].  
The activation of the MAP kinase cascade and in particular via the Ras/Raf/MAPK, occurs 
following the binding of growth factors to tyrosine kinase receptor localized on the membrane, which 
dimerize and interact with G proteins, represented by the Ras for via the ERK and Rho family 
members by way of JNK and p38. These proteins have GTP-ase activities and promote the 
phosphorylation of downstream proteins, including RAF, which is recruited to the membrane and 
phosphorylated. RAF phosphorylates MEK, which is able to always activate ERK by 
phosphorylation. The latter can activate several transcription factors such as c-MYC and CREB that 
promote cell proliferation while inhibiting the induction of apoptosis [103].  
Recent studies have demonstrated that activation of this pathway is correlated with the 
development of tumors, including renal cell carcinoma, genetic alterations of different pathway 
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components were observed with a frequency of about 20%, and in particular 'overexpression’ of some 
of these molecules was observed in 52% of renal cell carcinomas [104]  
JAK/STAT pathway 
The Signal Transducers and Activators of Transcription (STATs) are a family of cytoplasmic 
proteins with the function to transduce the signal coming from the extracellular environment to the 
nucleus; they are activated by phosphorylation of a tyrosine residue located in the C-terminal domain 
of the molecule; This phosphorylation is mediated by kinases belonging to the Janus family (JAK), 
which bind to the intracellular domain of the activated epidermal growth factor receptor; in this way 
is triggered dimerization of STATs, which occurs through the interaction between the tyrosine 
phosphorylated SH and domains present in these proteins; the homo-and heterodimers formed by 
STATs subsequently translocate to the nucleus where they regulate gene transcription.  
STAT3 is a family member that is activated STATs inappropriately in several forms of cancer. 
It seems that the continuous activation of STAT3 is sufficient for neoplastic transformation. The role 
of STATs proteins may depend on both post-translational modifications such as methylation and 
acetylation, and phosphorylation of serine residues operated by different kinases; impaired activation 
of the protein may, therefore, reflect both an increased activity of kinases regulating both epigenetic 
alterations that would alter the transcription of STAT3 [105]. 
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Figure 7. Main downstream signalling pathways regulated by EGFR 
 
The main mechanism of inactivation of EGFR, with a consequent reduction in numbers of the 
receptor, is represented by lysosomal degradation that follows endocytosis of the receptor-ligand 
complex. Recently it was shown that c-Cbl, enzyme with ubiquitin-ligase function, bind 
phosphorylated EGFR and mono-ubiquitylates several lysine residues allowing endocytosis and 
subsequent lysosome degradation. Mutations of c-Cbl have been identified in several types of 
malignancies; the mutated protein retains the ability to bind to tyrosine residues phosphorylated 
receptor tyrosine kinase, but is not able to ubiquitinate the receptor itself [106]. 
Recent results indicate a predominant role of VHL in the degradation of activated EGFR, the 
proposed mechanism involves the activation of constitutive HIF which suppresses the expression of 
rabaptina5, a transcriptional levels, a protein that plays an important role in mediating the fusion of 
endosomes with lysosomes; the loss of rabaptina5 is therefore responsible for the reduced lysosomal 
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degradation of the receptor. Moreover, VHL appears to play a dual role in the degradation of activated 
EGFR. In fact it was shown that the VHL promotes the poly-ubiquitination of EGFR activated, 
independently of c-Cbl, resulting receptor proteasomal degradation. Therefore, excessive kinase 
activity of EGFR in renal clear cell carcinomas, resulting in a growth advantage of the tumor, may be 
caused by failure of receptor inactivation in VHL-deficient tumor cells [107]. Moreover, in clear cell 
renal cell carcinomas with loss of VHL, HIF overexpression is responsible for an increased 
transcription of the gene of the transforming growth factor α (TGFα), an agonist of EGFR, and at the 
same time improves the efficiency of translation of the mRNA of the epidermal growth factor 
receptor. Increased expression of EGFR, thus, together with the increase in the levels of TGFα, may 
contribute to the progression of the tumor.  
EGFR targeted therapies 
Inhibition of the EGFR tyrosine kinase activity has been used for cancer therapy. Several 
studies conferred significant benefits from anti-EGFR agents in several types of solid tumors 
including colorectal, head and neck cancer, NSCLC and pancreatic cancer in terms of overall survival, 
progression free survival and overall response rate [108], however, other types of cancer are resistant 
to EGFR inhibitors such as Renal cell carcinoma and prostate cancer [109, 110].  
The complexity of EGFR-related signal transduction pathways and their importance for cell 
growth and survival highlights the potential role of EGFR alterations in the development and 
maintenance of cancer. Abnormalities in EGFR functions are associated will all key features of cancer 
development and growth, including autonomous cell proliferation, invasion, angiogenic and 
metastatic potential. Aberrant EGFR signaling can be initiated by several events, such as altered 
ligand production, receptor mutations or deletions, persistent activation.  
EGFR is frequently overexpressed in human tumors such as head and neck squamous cell 
carcinoma (HNSCC), glioblastoma, NSCL, breast, colorectal, bladder, prostate, ovarian carcinomas. 
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It has been for a long time the biomarker used for the application of Targeted Therapies. Other 
frequent alterations identified in the EGFR concern gene mutations that in approximately 90% of 
cases involve exons 18-24 coding for the tyrosine kinase domain of the receptor, resulting in a gain 
of function of the receptor. The amplification of the EGFR gene has rarely been shown in human 
tumors, although fluorescent in situ hybridization (FISH) has identified an increase in the gene copy 
number in tumor cells in approximately 25-40% of patients with carcinoma of the colon and rectum, 
lung and head and neck. These data suggest that inhibition of EGFR may be a viable therapeutic 
option in the treatment of cancer and it must be considered the functional involvement of EGFR in 
diverse cellular processes. 
Gene amplification leading to EGFR overexpression and often accompanied by other structural 
rearrangements that cause in-frame deletions in the extracellular domain of the receptor, the most 
frequent being the type III mutated variant of EGFR, denominated EGFRvIII. This mutated receptor 
is missing exons 2-7, which encode for a part of the dimerization arm and it is characterized by a 
deletion in the extracellular domain that leads to constitutive activation of its tyrosine kinase domain 
(Figure 8). EGFRvIII is expressed in tumors like breast, lung and ovarian carcinomas. Moreover, 
high EGFR expression seems to correlate with poor prognosis and worse clinical outcome in a large 
number of tumors. 
Several somatic mutations in the EGFR gene have been found to be linked with favorable 
response to the anti-EGFR tyrosine kinase inhibitors (TKI), Gefitinib and Erlotinib, in non–small cell 
lung cancer patients (40, 41). The mutations arise in four exons within the kinase domain of the 
receptor: point mutation of G719 in the exon 18, in-frame deletions of amino acids 746–750 in exon 
19, substitution of glycine to cysteine at codon 719 (G719C) in exon 19, amino acid substitution 
leucine to arginine at codon 858 (L858R) and leucine to glutamate at codon 861 (L861Q) in exon 21 
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[111, 112]. Conversely, some mutations are able to induce resistance to TKIs such as threonine to 
methionine (T790M or T766M) point mutations in exon 20 (Figure 9) [53,113].  
Recently two distinct therapeutic approaches have been developed for targeting EGFR: 
monoclonal antibodies (mAbs),which bind to the extracellular region of the receptor, inhibiting its 
dimerization and autophosphorylation (Cetuximab, Panitumumab) and small-molecule tyrosine 
kinase inhibitors (STKIs), which block receptor signaling by interfering with ATP binding to the 
receptor, as Gefitinib (Iressa) and Erlotinib (Tarceva), Lapatinib, Canertinib (Figure 10) [114].  
 
Figure 8. EGFR vIII mutant 
 
Figure 9. EGFR mutations and their frequency 
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Figure 10. Targeted therapies anti-EGFR 
SGLT1 (Sodium/GLucose co-Transporter 1) 
The use of EGFR in CCRCC as a therapeutic target in clinical trials with tyrosine kinase 
inhibitors did not earn any therapeutic efficacy. The lack of responsiveness to treatment with TKI that 
induce blocking the activation of downstream pathways suggests the presence of a function of EGFR 
which is not related to its kinase activity, by which the receptor could contribute to neoplastic 
progression. 
Evidence supported the existence of Kinase-independent function of EGFR. Several studies 
identified a link between glucose uptake performed by SGLT1, survival of cancer cells, and EGFR. 
A function of EGFR considered recently in oncology concerns its ability to promote glucose uptake 
into cancer cells by interacting with extracellular domain of SGLT1, through its kinase-independent 
mechanism, maintaining basal intracellular glucose level which avoids cell death and promotes cancer 
cells survival. A recent study demonstrated that the levels of SGLT1 and its transport activity vary 
with changes of the levels of EGFR protein. 
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SGLT1 is an active glucose transporter that exploits extracellular sodium concentration to 
transport glucose into cells independent of glucose concentration. This transporter plays an important 
role in maintaining glucose homeostasis both in normal cell physiology and in disease conditions. 
Weihua et al. observed that EGFR can stabilize SGLT1 by protein-protein interaction which 
leads to prevention of SGLT1 from proteosomal degradation. The kinase-irresponsive EGFR 
constantly interacts with proteins regardless of the presence of EGFR ligands and activation or 
inactivation of its tyrosine kinase. SGLT1 is one such protein that can bind to and keep EGFR in its 
kinase-irresponsive status [115]. 
One of the key features of tumor growth is that cancer cells consume greater amounts of 
nutrients and energy substrates than their non-pathological counterparts, showing an altered energy 
metabolism. This improved energy consumption require high rate of nutrient uptake, which is realize 
by overexpression of plasma membrane transporters. SGLT1 induction is used by cancer cell to 
enhance their glucose uptake and their glycolysis, so that cells obtain sufficient energy for 
maintaining their expansive growth.  
SGLT1 is overexpressed in different type of tumors, ovarian carcinoma, oral squamous cell 
carcinoma, colorectal carcinoma, pancreatic cancer and prostate cancer. In a recent study was 
observed that SGLT1 overexpression was significantly correlated with disease-free survival in 
pancreatic cancer [116, 117, 118, 119]. SGLT1 expression is also elevated in tumors with high 
expression of EGFR. 
In another study the authors measures the expression of both EGFR and SGLT1 and tested the 
effect of inhibition of SGLT1 in prostate cancer tissues. These data suggest that the treatment with a 
SGLT1 inhibitor sensitized cancer cells to EGFR TKI; furthermore, these data demonstrate that 
overexpression of SGLT1 protect renal epithelial cells and intestinal epithelial cells from apoptosis 
[120, 121]. The deletion of the EGFR-SGLT1 interacting domain promotes the down-regulation of 
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SGTL1 via the proteasome machinery, suggesting that disruption of EGFR–SGLT1 interaction in 
EGFR-positive cancer cells may lead to down-regulation of SGLT1. It is suggested that the EGFR–
SGLT1 interaction might be a novel therapeutic target for cancer treatment [120, 121]. 
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AIMS OF THE STUDY 
Pharmacological treatment by drugs targeted towards EGFR is more efficient in the treatment 
of those tumors that exhibit specific genetic abnormalities, such as mutations and amplification or 
increase in the number of copies of the EGFR gene [122], in the absence of mutations of genes that 
encode proteins located downstream. 
The expression of EGFR protein in CCRCC has been the subject of numerous studies, 
performed on large series of tumors, which showed that EGFR immunoreactivity is a very common 
occurrence, with a overexpression range of between 50% and 90%. [2, 123-128] 
Recent studies support the importance of EGFR prognostic impact in CCRCC, highlighting a 
positive correlation between protein overexpression and high-grade and stage of the disease, although 
this issue is still controversial in relation to previous experiences.  
Some studies showed an association of EGFR immunoreactivity with well differentiated RCCs, 
or regarded strong membranous EGFR immunostaining as an indicator of good prognosis, whereas 
others showed an association of EGFR immunoreactivity with high tumor stage/grade and poor 
prognosis, or no significant associations at all [129, 130].  
EGFR gene amplification and or mutations have rarely been identified in CCRCC, thus 
supporting  the results from clinical trials that demonstrate the lack of therapeutic response of this 
disease to the use of molecular anti- EGFR drugs. [130-135] 
Since in CCRCC genetic abnormalities responsible for EGFR protein overexpression are not 
apparently identifiable, EGFR overexpression should be related to alterations in the mechanisms of 
post-transcriptional regulation, with abnormal protein stabilization or defects in the degradation of 
the receptor, and consequent activation of receptor-mediated ligand. Similar mechanisms are 
involved in the biology of CCRCC, due to their specific genetic features, such as the loss of function 
of the VHL gene, resulting in a defective degradation of EGFR by poly-ubiquitination [107].  
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The aim of our study was to perform immunohistochemistry and molecular biology on a series 
of CCRCC to evaluate EGFR protein overexpression, the profile of gene expression and mutational 
status of the receptor, to correlate protein overexpression and gene overexpression, and to highlight 
the presence of any somatic mutations activating the receptor. 
Furthermore, we aimed to verify the functionality of the kinase receptor by 
immunohistochemical evaluation of some components of the main downstream signaling pathways, 
such as the RAS-RAF-MAPK, PI3K-AKT, and JAK-STAT.  
In addition, since it is known that EGFR possesses kinase-independent activities, which could 
justify its suggested role in the progression of cancer, we investigated the concurrent non-kinase role 
of EGFR expression by SGLT1 immunohistochemistry analysis. 
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MATERIALS AND METHODS 
Selection of patients 
A series of 34 CCRCC was selected from the archives of the Department of Histopathology of 
the University of Sassari. All the tumors in the sample group were reviewed and categorized 
according to the current classification system [21]. Three µm sections were obtained from formalin-
fixed, paraffin-embedded (FFPE) specimens, for haematoxylin and eosin stains and 
immunohistochemical analysis.  
From each selected sample 10 sections, 10 µm in thickness, were collected in sterile 
microcentrifuge tubes and used for the extraction of nucleic acids, used for performing genetic 
analysis. The healthy tissue of each sample was used as control.  
Immunohistochemistry 
Immunohistochemistry was performed on serial 4 µm sections from the 34 CCRCC and specific 
antibodies against EGFR, p-AKT, p-p44/42 MAPK, p-STAT3, SGLT1 were utilized. Sources, 
dilutions, antigen retrieval conditions and positive controls are summarized in Table 1. 
Immunohistochemistry for EGFR was performed with the EGFR pharmDx Kit (DakoCytomation, 
Glostrup, Denmark) according to manufacturer’s instructions, as previously described [135].  
Immunohistochemical results were then evaluated in a semi-quantitative manner and scored 
according to the intensity of immunostaining (1+, 2+, 3+) and the percentages of positively staining 
cells. Only cases with more than 1% of immunoreactive cells were considered as positive. Membrane 
and/or cytoplasmic immunoreactivity was also assessed for each positive case. 
Immunoreactions for p-AKT, p-p44/42 MAPK, p-STAT3, SGLT1were obtained by incubating 
sections with specific primary antibodies (150 µl) for 15 minutes. Immunodetection was performed 
using a non-biotin, highly sensitive system (Envision peroxidase detection system, DAKO, 
Carpinteria, CA, USA) consequently preventing possible false-positive staining owing to endogenous 
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biotin present in the tissue. The slides were then incubated with DAB substrate chromogen solution 
for 10 minutes and counterstained with hematoxylin. Appropriate positive controls were also 
concurrently stained. Staining intensity and percentage of positive cells were scored for each case, 
with subcellular localization of immunostaining also being assessed for each positive case. 
Fluorescence in situ hybridization (FISH) 
The slides were deparaffinized with two washes of xylene, 15 min each, and subsequently 
washed twice with absolute ethanol, 10 min each and then air dried in the hood. Next, the slides were 
treated with 0.1mM citric acid (pH 6.0) (Zymed, CA, USA) at 95°C for 10 min, rinsed in distilled 
water for 3 min followed by a wash of 2XSSC (standard saline citrate) for 5 min. Digestion of the 
tissue was performed by applying 0.4 ml of pepsin (5 mg/ml in 0.9% NaCl, pH 1.5) (Sigma, St Louis, 
MO, USA) at 37°C for 30 min. The slides were rinsed with distilled water for 3 min, then washed 
with 2XSSC for 5 min and air dried. 
Dual-color FISH was performed by using a mixture of a Spectrum green-labeled Centromeric 
α-satellite DNA probe (CEP7) and a Spectrum orange-labeled locus-specific DNA probe for EGFR 
gene. Both of the probes were from Vysis (Vysis, Downers Grove, IL, USA) and were diluted with 
tDenHyb2 (Insitus, Alburquerque, NM,USA) in a ratio of 1: 20. 
Five µl of diluted probes were added to the slide in the reduced light condition. The slides were 
covered with a 22X22mm cover slip and sealed with rubber cement. Denaturation was achieved by 
incubating the slides at 75°C for 10 min in a humidified box and then hybridized at 37°C over night. 
The coverslips were removed and the slides were washed with two washes at 45°C with 
0.1XSSC/1.5M urea (20 min for each wash), followed by a wash with 2XSSC for 20 min and a wash 
with 2XSSC/0.1% NP-40 for 10 min at 45°C. The slides were further washed with room temperature 
2XSSC for 5 min. The slides were air dried and counterstained with 10 ml DAPI (Insitus, 
Albuquerque, NM, USA), covered with coverslips and sealed with nail polish. The slides were 
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examined using an Olympus BX61 fluorescence microscope equipped with selective filters for the 
fluorochromes used. The images were acquired with a CCD camera and analyzed with Olympus DP-
Softimage analysis software. 
From each tumor section, 100 nuclei were scored for signals from LSI EGFR gene (orange) and 
CEP7 (green) under the fluorescence microscope with X1000 magnification and the ratio between 
orange and green signals was subsequently calculated; a tumor was considered amplified if the EGFR 
⁄CEP7 ratio was ≥ 2.0. 
Definition of chromosomal gain was based on the Gaussian model and related to the data from 
the normal renal parenchyma controls, as previously described [136]. Briefly, for each slide, at least 
100 nuclei were scored for signals from centromeric probes, under the fluorescence microscope with 
X1000 magnification, in both tumors and adjacent non-neoplastic renal parenchyma. The cut-off 
value for the definition of chromosome 7 gain was set at mean value plus three standard deviations 
(s.d.) of the percentages of nuclei with three or more signals in normal renal parenchyma. The mean 
percentage of nuclei with three or more signals was scored as 1,5, whereas the s.d. was assessed as 2. 
Therefore, the cut-off value to determine chromosomal gain in neoplastic specimens was 7.5. 
Nucleic Acids Extraction 
Ten consecutive sections, 10 m in thickness, were cut under sterile conditions from 
representative neoplastic tissue blocks of 34 CCRCC to obtain genomic DNA, and from the same 
neoplastic and non-neoplastic specimens, in order to obtain total RNA. Nucleic acids were extracted 
with a commercially available extraction kit (Rneasy FFPE Kit and QIAamp DNA FFPE Tissue Kit, 
Qiagen, Hilden, Germany) in accordance with the manufacturer’s instructions. To obtain genomic 
DNA 0.2 mg of RNase A (USB Corp., Cleveland Ohio, USA) were applied directly to the silica 
membrane to digest contaminating RNA. We assessed the quantity and the quality of nucleic acids 
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spectrophotometrically (260 nm, 260/280 and 260/230 ratios, spectrum 220-320 nm) using Nanodrop 
ND1000 (EuroClone, Milan, Italy). 
Reverse transcriptase reactions 
Three µg of total RNA were reverse transcribed to cDNA using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystem, Foster City, CA, USA), complying with the 
manufacturer’s instructions. The quality of the reverse transcription synthesis was tested by 
amplifying cDNA with primers of housekeeping genes (beta-actin and TBP) producing fragments of 
different lengths. 
Quantitative Real-Time PCR (qRT-PCR) 
Primers for EGFR (Hs01076078_m1, 60 bp), and 18S rRNA (Hs99999901_S1, 187 bp) human 
genes were chosen using Assays-on-DemandTM-Products (Applied Biosystems). Quantitative Real-
Time PCR was performed using TaqMan PCR chemistry and the ABI 7900HT Sequence Detection 
System (Applied Biosystems). A reaction volume of 50μl containing 300 nM of primer, 200 nM of 
probe and 54ng of reverse-transcribed RNA (based on the initial RNA concentration) was run using 
the TaqMan Universal PCR Master Mix (Applied Biosystems). Cycling conditions were: 10 minutes 
of denaturation at 95°C, 40 cycles at 95°C for 15 seconds and at 60°C for 1 minute. RNR18 was used 
as the reference gene for normalizing EGFR gene expression in Real-Time PCR. Duplicate reactions 
were performed in each cDNA sample and the relative mRNA expression level was analyzed 
according to Applied Biosystem User Bulletin N°2. The calculation 2-ΔΔCt (‘fold change’) was 
chosen to represent the level of expression, with a fold change of more than 2 being considered as 
over-expression. Data were expressed as medians and interquartile range according to a non-normal 
distribution of the variables [137, 138]. 
Mutation analysis 
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EGFR gene mutation analysis was performed on exons 18 to 24, coding for the tyrosine kinase 
receptor domain, which are known to harbour the most frequent and significant mutations for this 
gene (Table 2). Gene sequencing analysis was executed as previously reported [139] . 
Specifically, to detect EGFRvIII mutation, involving the deletion of exons 2 to 7, coding for 
the extracellular domain, a reverse transcription-PCR (RT-PCR) was developed. cDNAs were used 
to amplify the deletion region by primers in exon 1 (5’-GGGCTCTGGAGGAAAAGAAA-3’) and 
exon 8 (5’-CCTCCATCTCATGCTGTCG -3’), producing a 91bp or a 892bp PCR product for 
EGFRvIII and EGFR wild-type, respectively. 
PCR was performed in a finale volume of 20 μl, including 60ng of cDNA, 0,5 μM of each 
primer, 0.2 mM each of dATP, dCTP, dGTP, dTTP (Invitrogen, The Netherlands) 160mM 
(NH4)2SO4, 670 mMTris-HCl pH 8.8, 1.5 mM MgCl2, 5% DMSO, 2 U Super Taq (AB Analitica, 
Padova, Italy). PCR cycling conditions were: 5min at 94°C, 30 s at 95°C, 30 s at 60°C, 1 min at 72°C 
for 35 cycles, then 5min at 72°C. Cloned wild-type EGFR and EGFRvIII cDNA were used as control. 
Ten μl of PCR products were analyzed on a 2% agarose gel, stained with ethidium bromide. 
Statistical Analysis 
Statistical analysis was performed using the program Stata 11. The interaction between the 
clinical-pathological data and follow-up was performed by univariate analysis (p value). The 
comparison of the data related to the EGFR gene expression analysis in relation to histological types 
(neoplastic tissue to healthy tissue) were performed using non-parametric analysis by the Mann 
Whitney test. The limit of significance was set to p <0.05.  
Therefore, we assessed if there was a difference between SGLT1expression [in terms of 
intensity (scale 0-3), percentage of tumor cell (0-100%) and composite score, obtained by the 
multiplication of the intensity values * tumor cell percentage] and 4 classes of samples identified, 
where the first showed absence of EGFR signally pathways activation, the second activation of at 
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least one of the EGFR downstream pathways, the third two of the EGFR downstream pathways and 
the last showed activation of all EGFR pathways analyzed, using Kruskal-Wallis non-parametric 
statistical analysis. 
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Thirty-four cases of CCRCCs, comprehensive of 4 neoplasms with sarcomatoid features, were 
included in the study (Figure 11). Patients’ age ranged from 42 to 79 years (mean: 57.6), with 
predominance of males (20 cases) compared to females (14 cases). Tumor size varied between 2 and 
15 cm (mean: 7 cm). Five-years follow-up data showed no evidence of disease (NED) in 17 patients, 
whereas 14 patients developed distant metastases, and were alive with disease (AWD); only 3 
patients, all with distant metastases, died for the disease in the follow-up period. Further clinic-
pathologic features are summarized on Table 3, which includes the SSIGN score. 
Immunohistochemical analysis 
EGFR immunostaining was reported as membranous or membranous-cytoplasmic, whereas p-
AKT, and p-STAT3 showed nuclear staining, and p-p44/42 MAPK nuclear and/or cytoplasmic 
staining, as represented in Figure 11. EGFR expression was appreciable in 100% of the tumors, with 
the staining intensity ranging from 1+ to 3+, and percentages of positive cells varying from 20% to 
100%. No immunoreactivity was recognizable in non-neoplastic tissues.  
p-AKT expression was detected in 20 tumors (58.8%), with a 1+ to 3+ staining intensity and 
the range of positive cells being 10%–80%. p-p44/42 MAPK expression was identified in 18 tumors 
(52.9%), with a staining intensity of 1+ to 3+, and positive cell percentages between 5% and 90%.  
p-STAT3 expression was recognizable in 8 tumors (23.5%) with the staining intensity ranging 
from 1+ to 3+, and positive cells varying from 20% to 70%. Mild to moderate, nuclear and/or nuclear-
cytoplasmic immunoreactivity was also observed in endothelial cells of normal blood vessels, 
pericapsular adipose tissue and, focally, peritumoral renal tubules. Besides, p-AKT showed also 
nuclear immunostaining of renal pelvis urothelium. 
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Seven out of 34 tumors (20.6%) were characterized for the absence of p-AKT, p-p44/42 MAPK 
and p-STAT3expression, whereas 23 tumors (67.6) showed expression of at least 1 of the 3 
downstream signaling pathway members. Only 4 tumors displayed concurrent immunohistochemical 
expression of all the 3 pathways components. 
The membrane-cytoplasmic immunoreactivity for SGLT1 was detected in 31 of 34 cases 
(91.2%), with staining intensity between variable 1+ (15 cases), 2+ (11 cases) 3+ (5 cases); the 
percentage of immunoreactive neoplastic cells ranged between 10 and 90%. The positive control was 
represented by the epithelium of the proximal tubules, namely the luminal border, on the adjacent 
non-neoplastic renal parenchyma (Figure 11). 
In 77.4% of SGLT1-positive CCRCCs, it showed the simultaneous activation of the EGFR 
kinase. 
All the immunohistochemical results are summarized in Table 4. 
EGFR FISH analysis 
Gene amplification Ratio 
The data obtained for each tumor demonstrating the absence of amplification of the EGFR gene 
in all cases under study; in facts, EGFR/CEP7 signals ratios ranged from 0.99 to 1.13 (average 1.03), 
therefore constantly lower than the value (>2) established as amplification cut-off (Figure 12). 
Evaluation of chromosome 7 polysomy  
This assessment was made on the basis of the analysis of the number of centromeric signals 
detected in non-neoplastic parenchyma adjacent to the tumor. Establishing the values of cut-off as 
the average percentage (M) plus three standard deviations (3SD) for the nuclei with a single signal 
and the nuclei with three or more signals, it is obtained a value of 7.5% for the gain of chromosome 
7 (M = 1.5; SD = 2). Using the criteria for chromosome gain as described in Materials and Methods 
section, 11 tumors (32.3%) showed percentages of nuclei with three or more centromeric signals 
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below the cut-off value of 7.5%, ranging from 0 to 5% (mean: 2.9%), whereas 23 tumors (67.7%) 
were scored between 11 and 94% (mean: 44.9%), and considered to have gain of chromosome 7 
(polysomic). 
Expression Profiles Analysis 
EGFR mRNA expression levels were evaluated in only 30 tumors, because expression levels 
were not detectable on neoplastic and non-neoplastic tissues in 4 of 34 cases. 
Median values of EGFR expression level were evaluated as 3.18 (interquartile range, 1.71–
5.08) in CCRCC and 0.35 (interquartile range, 0.16–0.79) in the normal tissue. Statistical significance 
was found between tumor and normal tissue expression levels with P-values of 0.0003. qRT-PCR 
results are summarized in Figure 13. Fold change evaluation for each single tumor, compared with 
its normal counterpart, showed overexpression levels in 12 of 30 tumors (40%) with a range from 2-
fold to 17.5-fold. 
EGFR Mutational Analysis 
Genomic DNA sequencing of exons 18 to 24 coding for the receptor tyrosine kinase domain, 
which are known to harbor the most frequent and significant mutations for EGFR gene, failed to 
demonstrate mutations in any of the 34 cases studied. 
EGFR variant III (EGFRvIII) is an oncogenic, constitutively active mutant form of EGFR. 
EGFRvIII is generated by in-frame genomic deletion of 801bp from exons 2 to 7 of the coding region 
of EGFR which produces a truncated receptor lacking a portion of extracellular ligand binding 
domain. All 34 CCRCCs were investigated by RT-PCR to highlight this specific deletion, but no 
evidence of EGFRVIII deletion was found in our neoplastic series. 
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Statistical Analysis 
The univariate analysis of clinic-pathologic parameters with 5 years follow-up made it possible 
to show a strong prognostic correlation of patient survival with the following parameters: gender, 
grade according to Fuhrman, metastasis, tumor stage, high SSIGN score.  
No equivalent significant prognostic correlation for patient survival was detected either for 
immunohistochemical expression of p-AKT, p-p44/42 MAPK, p-STAT3, and SGLT1, or 
chromosome 7 polysomy or EGFR gene expression profile. (Table 5) 
The statistical analysis of the different classes of SGLT1 expression did not show any 
statistically significant difference (P> 0.05), might be due to a small number of samples in each class
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DISCUSSION 
Our study confirms that EGFR protein overexpression is a common molecular alteration in 
CCRCC.  
EGFR overexpression has been previously established in CCRCC, accounting for 70% of renal 
cell carcinomas with a range of 47% to 93.2%; the highest frequency and positivity was recognized 
in CCRCC variants than other renal tumors, such as papillary carcinoma and chromophobe carcinoma 
[2, 140].  
Our results also reveal the absence of EGFR amplification and high polysomy of chromosome 
7, and are in keeping with previous experiences described in literature [2,129,131]. 
Sakaeda et al in 2005 showed EGFR mRNA overexpression in all series of renal cell 
carcinomas analyzed  [141], while these results are partially confirmed in our study where the analysis 
of EGFR gene expression profile showed the presence of gene overexpression only in the 38.2% of 
CCRCC.  
According to our experimental study, we were able to identify three distinct molecular 
subgroups in our series of CCRCC: 13 samples (38.2%) were characterized by EGFR gene and 
protein overexpression and activation of downstream signaling pathways; 16 samples (47%) showed 
EGFR protein overexpression in the absence of gene overexpression, but still with activation of 
downstream signaling pathways; 5 samples (14.8%) displayed only EGFR protein overexpression, 
whereas neither EGFR gene overexpression nor pathway activation were detected. 
Our study demonstrates that CCRCC considered apparently as a molecular homogeneous 
tumor, is indeed more different biologically. The existence of different CCRCC subgroup can be 
sustained by the variability of the clinical behavior, as well as by the differences in treatment response. 
These molecular behaviors should be considered and analyzed for each patient, especially before 
proposing any treatment with biological targeted therapy. 
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The EGFR protein overexpression, not associated to gene overexpression but related to 
activation of signaling pathways, observed in some CCRCC analyzed might be related to the specific 
genetic alterations that characterize these tumors. Indeed, the main molecular mechanism involved in 
the CCRCC pathogenesis is the loss of VHL function [30, 36]. VHL gene encodes a cytoplasmic 
protein, that contribute at protein proteasomal degradation by complex with other ubiquitin-ligase 
proteins. VHL is able to reduce the EGFR protein expression by poly-ubiquitination and subsequent 
proteasomal degradation [107]. The EGFR stability showed in our samples might be due to the 
inactivation of VHL. Another mechanism responsible for EGFR degradation involves the protein c-
Cbl that endorses mono-ubiquitination of the receptor and its subsequent lysosomal degradation. 
Mutations of c-Cbl have been identified in several kinds of malignancies, the altered protein is able 
to bind phosphorylated tyrosine kinase receptor, but is not able to ubiquitinate it [106]. This could be 
an additional mechanism to increase the EGFR availability  in tumor cells. 
Moreover, loss of VHL function in tumor cells results in the stabilization of HIFα, with its 
consequent increased transcriptional activity. Specifically, the HIFα are associated with higher 
expression of TGF-alpha,  that is a main ligand of EGFR. Furthermore, HIFα increase the expression 
of caveolin 1, that under hypoxic conditions binds and promotes the dimerization and activation of 
EGFR in the absence of ligand [142]. Then, the stabilized protein EGFR can be activated both by an 
anomalous receptor dimerization in the absence of specific ligands, and by the production of TGF-
alpha [40]. The consequences are the activation of downstream signaling pathways, with enhance of 
growth, survival, motility and metabolism of neoplastic cells. 
Evidence supported the existence of Kinase-independent function of EGFR. Several studies 
identified a link between glucose uptake performed by SGLT1, survival of cancer cells, and EGFR 
[115]. A function of EGFR considered recently in oncology concerns its ability to promote glucose 
uptake into cancer cells by interacting with extracellular domain of SGLT1, through its kinase-
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independent mechanism, maintaining basal intracellular glucose level which avoids cell death and 
promotes cancer cells survival [115].  
Weihua et al. observed that EGFR can stabilize SGLT1 by protein-protein interaction which 
leads to prevention of SGLT1 from proteosomal degradation. The kinase-irresponsive EGFR 
constantly interacts with proteins regardless of the presence of EGFR ligands and activation or 
inactivation of its tyrosine kinase. SGLT1 is one such protein that can bind to and keep EGFR in its 
kinase-irresponsive status [115]. 
SGLT1 is overexpressed in different type of tumors, ovarian carcinoma, oral squamous cell 
carcinoma, colorectal carcinoma, pancreatic cancer and prostate cancer. A recent study demonstrated 
that SGLT1 overexpression was significantly correlated with disease-free survival in pancreatic 
cancer [116, 117, 118, 119]. SGLT1 expression is also elevated in tumors with high expression of 
EGFR. 
The potential relation between EGFR and SGLT1 was investigated in our study showing for 
the first time that SGLT1 is frequently overexpressed in CCRCC EGFR-positive, whit a SGLT1 
immunoreactivity detected in 31 of 34 cases (91.2%). Since the activation of downstream EGFR 
pathways is found in about 77% of SGLT1-positive CCRCC, it is conceivable that the functions 
kinase and non-kinase EGFR can be carried out independently of each other.  
Moreover, the existence of 14,8% of CCRCC with only EGFR protein overexpression and  
absence of activation signaling pathways, but with SGLT1 overexpression might explain the 
neoplastic progression of CCRCC in absence of kinase activity of EGFR.  
In fact, the use of EGFR in CCRCC as a therapeutic target in clinical trials with tyrosine kinase 
inhibitors did not earn any therapeutic efficacy. The lack of responsiveness to treatment with TKI, 
which induce blocking of downstream pathways, suggests the presence of a function of EGFR which 
is not related to its kinase activity, by which the receptor could contribute to neoplastic progression. 
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The deletion of the EGFR-SGLT1 interacting domain promotes the down-regulation of SGTL1 via 
the proteasome machinery, suggesting that disruption of EGFR–SGLT1 interaction in EGFR-positive 
cancer cells may lead to down-regulation of SGLT1.   
According to our results the interaction between EGFR/SGLT1 might be a novel therapeutic 




Table 1. Antibodies for immunohistochemical analyses 
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Primers Sequence Annealing 
Temperature 
Base pair 
EGFR F exon 18 GCTTGCAAGGACTCTGGGCT 
62°C 360 
EGFR R exon 18 CCAAACACTCAGTGAAACAAAGAG 
EGFR F exon 19 GTGCATCGCTGGTAACATCCA 
55°C 306 
EGFR R exon 19 CATTTAGGATGTGGAGATGAGC 
EGFR F exon 20 GAAACTCAAGATCGCATTCATGC 
60°C 379 
EGFR R exon 20 GCAAACTCTTGCTATCCCAGGAG 
EGFR F exon 21 CTAACGTTCGCCAGCCATAAGTCC 
57°C 370 
EGFR R exon 21 GCTCACCCAGAATGTCTGGA 
EGFR F exon 22 CACTCGTAATTAGGTCCAGAG 
55°C 295 
EGFR R exon 22 CTCAGTACAATAGATAGACAGCAATG 
EGFR F exon 23 CAAGACTACAGAAATGTAGGTTTC 
63°C 373 
EGFR R exon 23 GTGATGACATTTCTCCAGGGATGC 
EGFR F exon 24 CATCACCAATGCCTTCTTTAAGC 
59°C 310 
EGFR R exon 24 GCTGGAGGGTTTAATAATGCGATC 
 
  





























   n (%) 
Pathologic Tumor Classification   
pT1a   5 (14.7) 
pT1b   9 (26.5) 
pT2   7 (20.6) 
pT3a   7 (20.6) 
pT3b   5 (14.7) 
pT3c   1   (2.9) 
  
Regional Lymph Node Involvement  
pNx   7 (20.6) 
pN0 21 (61.8) 
pN1   3   (8.8) 
pN2   3   (8.8) 
  
Distant Metastasis  
M0 24 (70.6) 










  5 (14.7) 
  6 (17.6) 
12 (35.3) 
 
Fuhrman Nuclear Grade  
G1   1   (2.9) 
G2   8 (23.6) 
G3 16 (47.0) 
G4   9 (26.5) 
  
Necrosis  
Present 17 (50.0) 
Absent 17 (50.0) 
  
SSIGN Score  
0-2   6 (17.6) 
3-4   2   (5.9) 
5-6   7 (20.6) 
7-9   7 (20.6) 




Table 4 Immunohistochemistry results 
  EGFR p-AKT p-p44/42 MAPK p-STAT3 SGLT1 






























1 CCRCC 2+ 60 m 2+ 40 n 2+ 10 nc - - - 1+ 80 c 
2 CCRCC 3+ 60 mc 2+ 60 n 3+ 40 n - - - 2+ 70 mc 
3 CCRCC 2+ 70 mc - - - - - - - - - 1+ 70 mc 
4 CCRCC 2+ 70 m - - - - - - - - - 3+ 70 mc 
5 CCRCC 3+ 100 mc 1+ 50 n 1+ 10 n - - - 2+ 70 mc 
6 CCRCC 2+ 60 mc 1+ 10 n - - - - - - 3+ 80 mc 
8 CCRCC 1+ 40 m 3+ 80 n 3+ 90 n 3+ 70 n 2+ 80 mc 
9 CCRCC 3+ 90 mc 2+ 70 n 3+ 40 n 2+ 60 n 2+ 50 mc 
11 CCRCC 3+ 90 mc 2+ 70 n 2+ 40 n 2+ 50 n - - - 
12 CCRCC 3+ 90 mc - - - - - - 2+ 30 n 3+ 90 m 
13 CCRCC 1+ 20 m - - - - - - - - - 2+ 90 mc 
14 CCRCC 2+ 70 mc 2+ 60 n 3+ 20 nc - - - - - - 
15 CCRCC 2+ 90 mc 1+ 60 n - - - 2+ 40 n 2+ 80 mc 
16 CCRCC 3+ 90 mc - - - - - - - - - 3+ 80 mc 
17 CCRCC 3+ 80 mc - - - - - - - - - 3+ 80 mc 
18 CCRCC 3+ 95 m 1+ 10 n 2+ 60 n - - - 1+ 75 mc 
19 CCRCC 3+ 70 mc 1+ 10 n 2+ 20 n - - - 1+ 30 mc 
20 CCRCC 3+ 80 mc 1+ 15 - - - - - - - 1+ 25 m 
21 CCRCC 3+ 70 mc 1+ 25 n 2+ 10 n - - - 2+ 90 m 
22 CCRCC 2+ 75 m - - - 1+ 30 nc - - - 2+ 80 m 
23 CCRCC 3+ 80 mc - - - 1+ 40 n - - - 1+ 70 mc 
24 CCRCC 3+ 100 mc 1+ 40 n - - - - - - 2+ 60 mc 
26 CCRCC 3+ 60 m - - - 3+ 70 n - - - 1+ 70 mc 
27 CCRCC-S 3+ 95 mc - - - - - - 1+ 20 n 1+ 70 mc 
28 CCRCC 3+ 100 mc - - - 1+ 20 nc - - - 3+ 40 mc 
29 CCRCC 3+ 90 mc - - - 1+ 20 n - - - 1+ 60 mc 
30 CCRCC 3+ 90 mc 3+ 80 n 3+ 5 n - - - 1+ 90 mc 
31 CCRCC-S 2+ 65 mc - - - - - - - - - 1+ 30 m 
32 CCRCC 1+ 30 m 1+ 70 n - - - 3+ 20 n 2+ 60 m 
33 CCRCC 2+ 70 mc 3+ 80 n 3+ 20 n - - - 1+ 60 mc 
34 CCRCC 3+ 85 mc 1+ 40 n - - - - - - - - - 
35 CCRCC-S 3+ 90 mc 3+ 80 n 3+ 25 n 3+ 40 n 
3+ 80 mc 
36 CCRCC 3+ 100 mc 3+ 60 n - - - - - - 1+ 5 m 
37 CCRCC-S 3+ 90 mc - - - - - - - - - 3+ 80 mc 




Table 5. Univariate analysis for tumor specific survival in 






Age   0.5364 
≤50 9 100  
≥50 25 0  
    
Sex   0.0573 
Male 20 92.8  
Female 14 85.7  
    
Dimensions   0.5495 
≤5 10 90  
≥5 24 91.7  
    
Grading Fuhrman   0.0460 
G1+G2 9 100  
G3+G4 25 85.7  
    
Pathologic Tumor classification   0.0684 
pT1+pT2 21 95.2  
pT3 13 84.6  
    
Involvement of Regional lymphnodes   0.3339 
Nx+N0 28 92.8  
N1+N2 6 83.3  
    
Distant Metastasis   0.00001 
M0 24 100  
M+ 10 70  
    
pTNM Stage   0.0002 
I-II 16 100  
III-IV 18 83.3  
    
Necrosis   0.2982 
Present 17 94.1  
Absent 17 88.2  
    
SSIGN score   0.00001 
0-2 6 100  
3-4 2 100  
5-6 7 100  
7-9 7 100  
≥10 12 75  
    
IHC pAKT   0.06 
Positive 20 100  
Negative 14 78.6  
    
IHC p-p44/42 MAPK   0.6113 
Positive 18 100  
Negative 16 81.2  
    
IHC pSTAT3   0.7907 
Positive 8 100  
Negative 26 88.5  
    
IHC SGLT1   0.7630 
Positive 31 90.3  
Negative 3 100  
    
Chromosome 7 polisomy   0.2009 
Present 23 86.9  
Absent 11 100  
    
EGFR gene overexpression   0.5617 
Present 13 91.3  




Table 6. CCRCC molecular subgroups identified on the basis of EGFR gene expression 






































3 CCRCC 2+ 70 mc - - - - - - - - - 1+ 7 mc 0.54 
13 CCRCC 1+ 20 m - - - - - - - - - 2+ 90 mc 0,12 
16 CCRCC 3+ 90 mc - - - - - - - - - 3+ 80 mc 1.0 
17 CCRCC 3+ 80 mc - - - - - - - - - 3+ 80 mc 0,84 
37 CCRCC-S 3+ 90 mc - - - - - - - - - 3+ 80 mc 1,63 
                  
1 CCRCC 2+ 60 m 2+ 40 n 2+ 10 nc - - - 1+ 80 c 0.83 
2 CCRCC 3+ 60 mc 2+ 60 n 3+ 40 n - - - 2+ 70 m-c 0,95 
5 CCRCC 3+ 100 mc 1+ 50 n 1+ 10 n - - - 2+ 70 m-c 0,55 
8 CCRCC 1+ 40 m 3+ 80 n 3+ 90 n 3+ 70 n 2+ 80 m-c 0,93 
15 CCRCC 2+ 90 mc 1+ 60 n - - - 2+ 40 n 2+ 80 m-c 1,23 
18 CCRCC 3+ 95 m 1+ 10 n 2+ 60 n - - - 1+ 75 m-c 1,50 
19 CCRCC 3+ 70 mc 1+ 10 n 2+ 20 n - - - 1+ 30 m-c 0,65 
21 CCRCC 3+ 70 mc 1+ 25 n 2+ 10 n - - - 2+ 90 m 1,40 
22 CCRCC 2+ 75 m - - - 1+ 30 nc - - - 2+ 80 m 0,44 
24 CCRCC 3+ 100 mc 1+ 40 n - - - - - - 2+ 60 m-c 0,35 
27 CCRCC-S 3+ 95 mc - - - - - - 1+ 20 n 1+ 70 m-c 0.55 
28 CCRCC 3+ 100 mc - - - 1+ 20 nc - - - 3+ 40 m-c 0,50 
30 CCRCC 3+ 90 mc 3+ 80 n 3+ 5 n - - - 1+ 90 m-c 1.2 
33 CCRCC 2+ 70 mc 3+ 80 n 3+ 20 n - - - 1+ 60 m-c 1.5 
34 CCRCC 3+ 85 mc 1+ 40 n - - - - - - - - - 0,84 
36 CCRCC 3+ 100 mc 3+ 60 n - - - - - - 1+ 5 m 0,08 
 
4 CCRCC 2+ 70 m - - - - - - - - - 3+ 70 m-c 5,43 
6 CCRCC 2+ 60 m-c 1+ 10 n 1+ < n - - - 3+ 80 m-c 4,03 
9 CCRCC 3+ 90 m-c 2+ 70 n 3+ 40 n 2+ 60 n 2+ 50 m-c 3,23 
11 CCRCC 3+ 90 m-c 2+ 70 n 2+ 40 n 2+ 50 n - - - 3,9 
12 CCRCC 3+ 90 m-c 1+ <5 n - - - 2+ 30 n 3+ 90 m 3,82 
14 CCRCC 2+ 70 m-c 2+ 60 n 3+ 20 n-c - - - - - - 2,97 
20 CCRCC 3+ 80 m-c 1+ 15 n - - - - - - 1+ 25 m 8,29 
23 CCRCC 3+ 80 m-c 1+ <5 n 1+ 40 n - - - 1+ 70 m-c 2,46 
26 CCRCC 3+ 60 m - - - 3+ 70 n - - - 1+ 70 m-c 2,33 
29 CCRCC 3+ 90 m-c - - - 2+ 20 n - - - 1+ 60 m-c 6,58 
31 CCRCC-S 2+ 65 m-c - - - - - - - - - 1+ 30 m 2,35 
32 CCRCC 1+ 30 m 1+ 70 n - - - 3+ 20 n 2+ 60 m 10,97 











































Figure 11. Morphologic and immunohistochemical features of clear cell renal cell carcinoma. a. Haematoxylin & Eosin stain 
illustrates the typical CCRCC features; b. Haematoxylin & Eosin stain illustrates the sarcomatoid CCRCC features. c. Immunostaining 
for EGFR displaying diffuse and intense membranous and cytoplasmic; d. Immunostaining for p-AKT showing intense and diffuse 
nuclear immunoreactivity; e. Immunostaining for p-p44/42 MAPK showing focal and intense nuclear-cytoplasmic immunoreactivity; 
f. Immunostaining for pSTAT3 displaying nuclear and moderate immunoreactivity; g. Immunostaining for SGLT1 displaying diffuse 














Figure 12: FISH analysis in clear cell renal cell carcinoma. a. FISH with centromeric probe for chromosome 7 showing 
nuclei with two green hybridization signals close two EGFR gene (red hybridization signals), consistent with absence of EGFR 
amplification b. FISH with centromeric probe for chromosome 7 showing nuclei with four green hybridization signals close 





















CCRCC EGFR Normal EGFR
Figure 13. Real-time polymerase chain reaction analysis for EGFR. Box and whisker plots were used 
to summarize the distribution of mRNA levels in clear cell renal cell carcinoma and normal tissue controls. 
Statistical analysis by Mann Whitney test show significant differences in mRNA levels between 
neoplastic and non-neoplastic tissues for EGFR gene expression, with P-value of 0.0003. The horizontal 
line in the box represents the 50% (median) and the upper and the lower lines of the box represent 75% 
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